EA016001B1 - Трициклические соединения и их применение в качестве модуляторов глюкокортикоидного рецептора - Google Patents

Info

Publication number

EA016001B1

EA016001B1 EA200970662A EA200970662A EA016001B1 EA 016001 B1 EA016001 B1 EA 016001B1 EA 200970662 A EA200970662 A EA 200970662A EA 200970662 A EA200970662 A EA 200970662A EA 016001 B1 EA016001 B1 EA 016001B1

Authority

EA

Eurasian Patent Office

Prior art keywords

receptor

compound

compounds

kinase

disease

Prior art date

2007-02-02

Links

• Espacenet
• Global Dossier
• Discuss

• 150000001875 compounds Chemical class 0.000 title claims abstract description 205
• 229940117965 Glucocorticoid receptor modulator Drugs 0.000 title description 5
• 150000003839 salts Chemical class 0.000 claims abstract description 88
• 230000000694 effects Effects 0.000 claims abstract description 40
• 102000003676 Glucocorticoid Receptors Human genes 0.000 claims abstract description 26
• 108090000079 Glucocorticoid Receptors Proteins 0.000 claims abstract description 26
• 230000001404 mediated effect Effects 0.000 claims abstract description 11
• 208000006673 asthma Diseases 0.000 claims description 46
• 238000000034 method Methods 0.000 claims description 41
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 12
• 206010039073 rheumatoid arthritis Diseases 0.000 claims description 12
• 206010061218 Inflammation Diseases 0.000 claims description 11
• 230000004054 inflammatory process Effects 0.000 claims description 11
• 201000004624 Dermatitis Diseases 0.000 claims description 10
• 230000001684 chronic effect Effects 0.000 claims description 7
• 208000024827 Alzheimer disease Diseases 0.000 claims description 6
• 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 6
• 206010046851 Uveitis Diseases 0.000 claims description 4
• 208000028017 Psychotic disease Diseases 0.000 claims description 3
• 206010052779 Transplant rejections Diseases 0.000 claims description 3
• 201000006417 multiple sclerosis Diseases 0.000 claims description 3
• 208000033808 peripheral neuropathy Diseases 0.000 claims description 3
• QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims description 2
• 230000000116 mitigating effect Effects 0.000 claims description 2
• 201000001119 neuropathy Diseases 0.000 claims description 2
• 230000007823 neuropathy Effects 0.000 claims description 2
• 239000008194 pharmaceutical composition Substances 0.000 claims 1
• 238000011282 treatment Methods 0.000 abstract description 30
• 239000000203 mixture Substances 0.000 description 85
• 102000005962 receptors Human genes 0.000 description 73
• 108020003175 receptors Proteins 0.000 description 73
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 50
• -1 2-methylpyridin-3-yl Chemical group 0.000 description 48
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 43
• 230000005764 inhibitory process Effects 0.000 description 37
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 36
• 201000010099 disease Diseases 0.000 description 34
• 239000003112 inhibitor Substances 0.000 description 27
• 239000007787 solid Substances 0.000 description 27
• 210000004027 cell Anatomy 0.000 description 26
• 102000004067 Osteocalcin Human genes 0.000 description 25
• 108090000573 Osteocalcin Proteins 0.000 description 25
• 239000005557 antagonist Substances 0.000 description 23
• 239000000243 solution Substances 0.000 description 22
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
• 238000002360 preparation method Methods 0.000 description 21
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
• 241000699670 Mus sp. Species 0.000 description 20
• 238000006243 chemical reaction Methods 0.000 description 20
• 108091000080 Phosphotransferase Proteins 0.000 description 19
• 102000020233 phosphotransferase Human genes 0.000 description 19
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
• 238000004519 manufacturing process Methods 0.000 description 18
• 210000004369 blood Anatomy 0.000 description 17
• 239000008280 blood Substances 0.000 description 17
• 206010006451 bronchitis Diseases 0.000 description 17
• 229960004618 prednisone Drugs 0.000 description 16
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 16
• QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 16
• 239000002904 solvent Substances 0.000 description 16
• 108090000623 proteins and genes Proteins 0.000 description 15
• 239000003826 tablet Substances 0.000 description 15
• 229960005205 prednisolone Drugs 0.000 description 14
• OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 14
• 235000018102 proteins Nutrition 0.000 description 14
• 102000004169 proteins and genes Human genes 0.000 description 14
• 238000010494 dissociation reaction Methods 0.000 description 13
• 230000005593 dissociations Effects 0.000 description 13
• 239000003814 drug Substances 0.000 description 13
• 238000005481 NMR spectroscopy Methods 0.000 description 12
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
• 239000002552 dosage form Substances 0.000 description 12
• 239000002609 medium Substances 0.000 description 12
• LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 12
• 210000002966 serum Anatomy 0.000 description 12
• 210000000988 bone and bone Anatomy 0.000 description 11
• 239000003795 chemical substances by application Substances 0.000 description 11
• 229940079593 drug Drugs 0.000 description 11
• 238000009472 formulation Methods 0.000 description 11
• 239000003446 ligand Substances 0.000 description 11
• 230000001225 therapeutic effect Effects 0.000 description 11
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 11
• RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 10
• 239000007921 spray Substances 0.000 description 10
• 239000000725 suspension Substances 0.000 description 10
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 9
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 9
• 201000009267 bronchiectasis Diseases 0.000 description 9
• 239000000047 product Substances 0.000 description 9
• 239000011541 reaction mixture Substances 0.000 description 9
• 102000009410 Chemokine receptor Human genes 0.000 description 8
• 108050000299 Chemokine receptor Proteins 0.000 description 8
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 8
• 239000002253 acid Substances 0.000 description 8
• 230000003111 delayed effect Effects 0.000 description 8
• CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 8
• 239000007788 liquid Substances 0.000 description 8
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 8
• 230000011164 ossification Effects 0.000 description 8
• 239000000843 powder Substances 0.000 description 8
• 230000001629 suppression Effects 0.000 description 8
• 102000003390 tumor necrosis factor Human genes 0.000 description 8
• 108091006146 Channels Proteins 0.000 description 7
• 229940126062 Compound A Drugs 0.000 description 7
• NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 7
• 102000001253 Protein Kinase Human genes 0.000 description 7
• 239000002585 base Substances 0.000 description 7
• JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 7
• 230000001419 dependent effect Effects 0.000 description 7
• 239000003085 diluting agent Substances 0.000 description 7
• 239000012074 organic phase Substances 0.000 description 7
• 229940002612 prodrug Drugs 0.000 description 7
• 239000000651 prodrug Substances 0.000 description 7
• 108060006633 protein kinase Proteins 0.000 description 7
• 239000007858 starting material Substances 0.000 description 7
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
• 239000000556 agonist Substances 0.000 description 6
• 230000001363 autoimmune Effects 0.000 description 6
• 229940125904 compound 1 Drugs 0.000 description 6
• VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
• 238000002474 experimental method Methods 0.000 description 6
• 108010044426 integrins Proteins 0.000 description 6
• 102000006495 integrins Human genes 0.000 description 6
• 239000000543 intermediate Substances 0.000 description 6
• 201000010659 intrinsic asthma Diseases 0.000 description 6
• 210000001503 joint Anatomy 0.000 description 6
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
• 230000008506 pathogenesis Effects 0.000 description 6
• 239000012071 phase Substances 0.000 description 6
• 210000003491 skin Anatomy 0.000 description 6
• 238000012360 testing method Methods 0.000 description 6
• LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 6
• 229960002004 valdecoxib Drugs 0.000 description 6
• TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 5
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 5
• HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 5
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
• 102000003960 Ligases Human genes 0.000 description 5
• 108090000364 Ligases Proteins 0.000 description 5
• IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 5
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 5
• 229960001138 acetylsalicylic acid Drugs 0.000 description 5
• 239000012190 activator Substances 0.000 description 5
• 230000001154 acute effect Effects 0.000 description 5
• 229940035676 analgesics Drugs 0.000 description 5
• 239000000730 antalgic agent Substances 0.000 description 5
• 229910002091 carbon monoxide Inorganic materials 0.000 description 5
• 229960000590 celecoxib Drugs 0.000 description 5
• RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 5
• 230000001054 cortical effect Effects 0.000 description 5
• 239000003246 corticosteroid Substances 0.000 description 5
• 229960001334 corticosteroids Drugs 0.000 description 5
• 238000004821 distillation Methods 0.000 description 5
• 239000001257 hydrogen Substances 0.000 description 5
• 229910052739 hydrogen Inorganic materials 0.000 description 5
• 229960001680 ibuprofen Drugs 0.000 description 5
• 208000030603 inherited susceptibility to asthma Diseases 0.000 description 5
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 5
• 229960005489 paracetamol Drugs 0.000 description 5
• 229940044551 receptor antagonist Drugs 0.000 description 5
• 239000002464 receptor antagonist Substances 0.000 description 5
• 229940083542 sodium Drugs 0.000 description 5
• 239000011734 sodium Substances 0.000 description 5
• 229910052708 sodium Inorganic materials 0.000 description 5
• 208000011580 syndromic disease Diseases 0.000 description 5
• 210000001519 tissue Anatomy 0.000 description 5
• 229960004380 tramadol Drugs 0.000 description 5
• TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 5
• 239000003981 vehicle Substances 0.000 description 5
• CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 4
• 208000011231 Crohn disease Diseases 0.000 description 4
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
• 208000003456 Juvenile Arthritis Diseases 0.000 description 4
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
• 241000699666 Mus <mouse, genus> Species 0.000 description 4
• 239000002202 Polyethylene glycol Substances 0.000 description 4
• 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 4
• 102000015433 Prostaglandin Receptors Human genes 0.000 description 4
• 108010050183 Prostaglandin Receptors Proteins 0.000 description 4
• 241000700159 Rattus Species 0.000 description 4
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
• 230000003110 anti-inflammatory effect Effects 0.000 description 4
• 239000000935 antidepressant agent Substances 0.000 description 4
• 229940005513 antidepressants Drugs 0.000 description 4
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
• 239000000969 carrier Substances 0.000 description 4
• 239000003153 chemical reaction reagent Substances 0.000 description 4
• NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 4
• 239000007884 disintegrant Substances 0.000 description 4
• 239000012458 free base Substances 0.000 description 4
• 230000001965 increasing effect Effects 0.000 description 4
• 229960000905 indomethacin Drugs 0.000 description 4
• 208000015181 infectious disease Diseases 0.000 description 4
• 208000027866 inflammatory disease Diseases 0.000 description 4
• 230000002757 inflammatory effect Effects 0.000 description 4
• 230000000968 intestinal effect Effects 0.000 description 4
• 239000008101 lactose Substances 0.000 description 4
• 238000005259 measurement Methods 0.000 description 4
• 229960003940 naproxen sodium Drugs 0.000 description 4
• CDBRNDSHEYLDJV-FVGYRXGTSA-M naproxen sodium Chemical compound [Na+].C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CDBRNDSHEYLDJV-FVGYRXGTSA-M 0.000 description 4
• 230000000414 obstructive effect Effects 0.000 description 4
• 239000000546 pharmaceutical excipient Substances 0.000 description 4
• 229920001223 polyethylene glycol Polymers 0.000 description 4
• 150000003180 prostaglandins Chemical class 0.000 description 4
• ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 4
• 210000002345 respiratory system Anatomy 0.000 description 4
• 208000023504 respiratory system disease Diseases 0.000 description 4
• 239000011550 stock solution Substances 0.000 description 4
• 125000000446 sulfanediyl group Chemical group *S* 0.000 description 4
• 230000008961 swelling Effects 0.000 description 4
• FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 4
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
• 102100026802 72 kDa type IV collagenase Human genes 0.000 description 3
• 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 3
• 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 description 3
• 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 3
• 206010006458 Bronchitis chronic Diseases 0.000 description 3
• 101710117545 C protein Proteins 0.000 description 3
• 108060001064 Calcitonin Proteins 0.000 description 3
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
• 206010009900 Colitis ulcerative Diseases 0.000 description 3
• 108010037462 Cyclooxygenase 2 Proteins 0.000 description 3
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 3
• 108010036949 Cyclosporine Proteins 0.000 description 3
• 102000004127 Cytokines Human genes 0.000 description 3
• 108090000695 Cytokines Proteins 0.000 description 3
• 206010014561 Emphysema Diseases 0.000 description 3
• 102100029112 Endothelin-converting enzyme 1 Human genes 0.000 description 3
• 102100038595 Estrogen receptor Human genes 0.000 description 3
• 108010008165 Etanercept Proteins 0.000 description 3
• 108010010803 Gelatin Proteins 0.000 description 3
• 241000282412 Homo Species 0.000 description 3
• 206010020751 Hypersensitivity Diseases 0.000 description 3
• 102000012355 Integrin beta1 Human genes 0.000 description 3
• 108010022222 Integrin beta1 Proteins 0.000 description 3
• 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 3
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
• 108010075654 MAP Kinase Kinase Kinase 1 Proteins 0.000 description 3
• 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 3
• 241001465754 Metazoa Species 0.000 description 3
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
• 102100033115 Mitogen-activated protein kinase kinase kinase 1 Human genes 0.000 description 3
• 102100033059 Mitogen-activated protein kinase kinase kinase 3 Human genes 0.000 description 3
• 102100033127 Mitogen-activated protein kinase kinase kinase 5 Human genes 0.000 description 3
• 102000010909 Monoamine Oxidase Human genes 0.000 description 3
• 108010062431 Monoamine oxidase Proteins 0.000 description 3
• HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 3
• LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
• 206010028980 Neoplasm Diseases 0.000 description 3
• 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 3
• 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 3
• 108091006764 Organic cation transporters Proteins 0.000 description 3
• 108091007960 PI3Ks Proteins 0.000 description 3
• 208000002193 Pain Diseases 0.000 description 3
• 102000035195 Peptidases Human genes 0.000 description 3
• 108091005804 Peptidases Proteins 0.000 description 3
• 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 3
• 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 3
• 108090000315 Protein Kinase C Proteins 0.000 description 3
• 102000003923 Protein Kinase C Human genes 0.000 description 3
• 201000004681 Psoriasis Diseases 0.000 description 3
• 201000001263 Psoriatic Arthritis Diseases 0.000 description 3
• 208000036824 Psoriatic arthropathy Diseases 0.000 description 3
• RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
• 229920002472 Starch Polymers 0.000 description 3
• 210000001744 T-lymphocyte Anatomy 0.000 description 3
• 229940123445 Tricyclic antidepressant Drugs 0.000 description 3
• 201000006704 Ulcerative Colitis Diseases 0.000 description 3
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 3
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
• 238000010521 absorption reaction Methods 0.000 description 3
• 230000004913 activation Effects 0.000 description 3
• 239000000443 aerosol Substances 0.000 description 3
• 239000013566 allergen Substances 0.000 description 3
• 208000026935 allergic disease Diseases 0.000 description 3
• 102000030619 alpha-1 Adrenergic Receptor Human genes 0.000 description 3
• 108020004102 alpha-1 Adrenergic Receptor Proteins 0.000 description 3
• 238000004458 analytical method Methods 0.000 description 3
• 229940124599 anti-inflammatory drug Drugs 0.000 description 3
• 239000000427 antigen Substances 0.000 description 3
• 108091007433 antigens Proteins 0.000 description 3
• 102000036639 antigens Human genes 0.000 description 3
• 206010003246 arthritis Diseases 0.000 description 3
• 230000001580 bacterial effect Effects 0.000 description 3
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
• 239000011230 binding agent Substances 0.000 description 3
• 239000000090 biomarker Substances 0.000 description 3
• 230000015572 biosynthetic process Effects 0.000 description 3
• DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 3
• 239000011575 calcium Substances 0.000 description 3
• 229910052791 calcium Inorganic materials 0.000 description 3
• 239000003054 catalyst Substances 0.000 description 3
• 238000004587 chromatography analysis Methods 0.000 description 3
• 208000007451 chronic bronchitis Diseases 0.000 description 3
• 229960001265 ciclosporin Drugs 0.000 description 3
• 208000010247 contact dermatitis Diseases 0.000 description 3
• 239000012043 crude product Substances 0.000 description 3
• 229930182912 cyclosporin Natural products 0.000 description 3
• 230000006378 damage Effects 0.000 description 3
• 238000007405 data analysis Methods 0.000 description 3
• 229960003638 dopamine Drugs 0.000 description 3
• 229960000403 etanercept Drugs 0.000 description 3
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
• 230000005713 exacerbation Effects 0.000 description 3
• 239000000945 filler Substances 0.000 description 3
• 239000012530 fluid Substances 0.000 description 3
• 210000002683 foot Anatomy 0.000 description 3
• 230000002538 fungal effect Effects 0.000 description 3
• 239000008273 gelatin Substances 0.000 description 3
• 229920000159 gelatin Polymers 0.000 description 3
• 235000019322 gelatine Nutrition 0.000 description 3
• 235000011852 gelatine desserts Nutrition 0.000 description 3
• 238000004128 high performance liquid chromatography Methods 0.000 description 3
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
• 230000009610 hypersensitivity Effects 0.000 description 3
• 230000002458 infectious effect Effects 0.000 description 3
• 239000007924 injection Substances 0.000 description 3
• 238000002347 injection Methods 0.000 description 3
• 239000010410 layer Substances 0.000 description 3
• 239000000314 lubricant Substances 0.000 description 3
• 235000019359 magnesium stearate Nutrition 0.000 description 3
• 239000000463 material Substances 0.000 description 3
• 239000003771 matrix metalloproteinase inhibitor Substances 0.000 description 3
• 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 description 3
• 229960000485 methotrexate Drugs 0.000 description 3
• 229920000609 methyl cellulose Polymers 0.000 description 3
• 235000010981 methylcellulose Nutrition 0.000 description 3
• 239000001923 methylcellulose Substances 0.000 description 3
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
• 239000008108 microcrystalline cellulose Substances 0.000 description 3
• 229940016286 microcrystalline cellulose Drugs 0.000 description 3
• 150000004682 monohydrates Chemical class 0.000 description 3
• 230000003551 muscarinic effect Effects 0.000 description 3
• 229960002378 oftasceine Drugs 0.000 description 3
• 201000008482 osteoarthritis Diseases 0.000 description 3
• 238000007911 parenteral administration Methods 0.000 description 3
• 230000003285 pharmacodynamic effect Effects 0.000 description 3
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
• 229910052698 phosphorus Inorganic materials 0.000 description 3
• 239000011591 potassium Substances 0.000 description 3
• 229960003975 potassium Drugs 0.000 description 3
• 229910052700 potassium Inorganic materials 0.000 description 3
• 230000004044 response Effects 0.000 description 3
• 229960002073 sertraline Drugs 0.000 description 3
• VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 3
• 239000002356 single layer Substances 0.000 description 3
• QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 3
• 239000008107 starch Substances 0.000 description 3
• 235000019698 starch Nutrition 0.000 description 3
• 229940032147 starch Drugs 0.000 description 3
• 238000003756 stirring Methods 0.000 description 3
• 229960005322 streptomycin Drugs 0.000 description 3
• 239000004094 surface-active agent Substances 0.000 description 3
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 3
• 210000002303 tibia Anatomy 0.000 description 3
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
• 230000000699 topical effect Effects 0.000 description 3
• 238000012546 transfer Methods 0.000 description 3
• 239000003029 tricyclic antidepressant agent Substances 0.000 description 3
• 230000003612 virological effect Effects 0.000 description 3
• AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 2
• SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
• RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 2
• PJDWNSYGMXODTB-UHFFFAOYSA-N 1,2,3,4,4a,4b,5,6-octahydrophenanthrene Chemical compound C1=CCCC2C(CCCC3)C3=CC=C21 PJDWNSYGMXODTB-UHFFFAOYSA-N 0.000 description 2
• QWUWMCYKGHVNAV-UHFFFAOYSA-N 1,2-dihydrostilbene Chemical group C=1C=CC=CC=1CCC1=CC=CC=C1 QWUWMCYKGHVNAV-UHFFFAOYSA-N 0.000 description 2
• ZSFPJJJRNUZCEV-UHFFFAOYSA-N 2-methylpyridin-3-amine Chemical compound CC1=NC=CC=C1N ZSFPJJJRNUZCEV-UHFFFAOYSA-N 0.000 description 2
• VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 2
• ZDRVLAOYDGQLFI-UHFFFAOYSA-N 4-[[4-(4-chlorophenyl)-1,3-thiazol-2-yl]amino]phenol;hydrochloride Chemical compound Cl.C1=CC(O)=CC=C1NC1=NC(C=2C=CC(Cl)=CC=2)=CS1 ZDRVLAOYDGQLFI-UHFFFAOYSA-N 0.000 description 2
• 108091005482 5-HT4 receptors Proteins 0.000 description 2
• 102000008813 5-Hydroxytryptamine 4 receptors Human genes 0.000 description 2
• 102000050060 5-Hydroxytryptamine 6 receptors Human genes 0.000 description 2
• 108700039170 5-Hydroxytryptamine 6 receptors Proteins 0.000 description 2
• 102000019325 5-Hydroxytryptamine 7 receptors Human genes 0.000 description 2
• 108090000411 5-Lipoxygenase-Activating Proteins Proteins 0.000 description 2
• 102000004023 5-Lipoxygenase-Activating Proteins Human genes 0.000 description 2
• 101710151806 72 kDa type IV collagenase Proteins 0.000 description 2
• 102100033639 Acetylcholinesterase Human genes 0.000 description 2
• 108010022752 Acetylcholinesterase Proteins 0.000 description 2
• 102000018918 Activin Receptors Human genes 0.000 description 2
• 108010052946 Activin Receptors Proteins 0.000 description 2
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
• 208000026872 Addison Disease Diseases 0.000 description 2
• 208000020576 Adrenal disease Diseases 0.000 description 2
• 102000001838 Angiotensin II receptor type 1 Human genes 0.000 description 2
• 108050009086 Angiotensin II receptor type 1 Proteins 0.000 description 2
• 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
• 101100167439 Arabidopsis thaliana CLPC1 gene Proteins 0.000 description 2
• 101100509022 Arabidopsis thaliana IRM1 gene Proteins 0.000 description 2
• 239000004475 Arginine Substances 0.000 description 2
• 206010003267 Arthritis reactive Diseases 0.000 description 2
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
• 206010003645 Atopy Diseases 0.000 description 2
• 101710085045 B2 bradykinin receptor Proteins 0.000 description 2
• 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 2
• 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 2
• 241000283690 Bos taurus Species 0.000 description 2
• 102000055006 Calcitonin Human genes 0.000 description 2
• 101000809436 Candida albicans Sterol O-acyltransferase 2 Proteins 0.000 description 2
• 241000282472 Canis lupus familiaris Species 0.000 description 2
• 102100033868 Cannabinoid receptor 1 Human genes 0.000 description 2
• 101710187010 Cannabinoid receptor 1 Proteins 0.000 description 2
• 102100036214 Cannabinoid receptor 2 Human genes 0.000 description 2
• 101710187022 Cannabinoid receptor 2 Proteins 0.000 description 2
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
• BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
• 108010078791 Carrier Proteins Proteins 0.000 description 2
• 102000052052 Casein Kinase II Human genes 0.000 description 2
• 108010010919 Casein Kinase II Proteins 0.000 description 2
• 102100035904 Caspase-1 Human genes 0.000 description 2
• 108090000426 Caspase-1 Proteins 0.000 description 2
• 108010076667 Caspases Proteins 0.000 description 2
• 102000011727 Caspases Human genes 0.000 description 2
• 108010012236 Chemokines Proteins 0.000 description 2
• 102000019034 Chemokines Human genes 0.000 description 2
• 102000004859 Cholecystokinin Receptors Human genes 0.000 description 2
• 108090001085 Cholecystokinin Receptors Proteins 0.000 description 2
• 208000002691 Choroiditis Diseases 0.000 description 2
• 102100029117 Coagulation factor X Human genes 0.000 description 2
• 102000000503 Collagen Type II Human genes 0.000 description 2
• 108010041390 Collagen Type II Proteins 0.000 description 2
• 102100027995 Collagenase 3 Human genes 0.000 description 2
• 108090000044 Complement Factor I Proteins 0.000 description 2
• 102100035431 Complement factor I Human genes 0.000 description 2
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
• 108020004414 DNA Proteins 0.000 description 2
• 206010012442 Dermatitis contact Diseases 0.000 description 2
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
• 102000015554 Dopamine receptor Human genes 0.000 description 2
• 108050004812 Dopamine receptor Proteins 0.000 description 2
• 102100023275 Dual specificity mitogen-activated protein kinase kinase 3 Human genes 0.000 description 2
• 102100023274 Dual specificity mitogen-activated protein kinase kinase 4 Human genes 0.000 description 2
• 102100023332 Dual specificity mitogen-activated protein kinase kinase 7 Human genes 0.000 description 2
• 208000000059 Dyspnea Diseases 0.000 description 2
• 206010013975 Dyspnoeas Diseases 0.000 description 2
• 102100031780 Endonuclease Human genes 0.000 description 2
• 102000004190 Enzymes Human genes 0.000 description 2
• 108090000790 Enzymes Proteins 0.000 description 2
• 102000003951 Erythropoietin Human genes 0.000 description 2
• 108090000394 Erythropoietin Proteins 0.000 description 2
• 208000009386 Experimental Arthritis Diseases 0.000 description 2
• 108010014173 Factor X Proteins 0.000 description 2
• 108090000368 Fibroblast growth factor 8 Proteins 0.000 description 2
• 206010017533 Fungal infection Diseases 0.000 description 2
• UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• 108010070600 Glucose-6-phosphate isomerase Proteins 0.000 description 2
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
• 201000005569 Gout Diseases 0.000 description 2
• 208000030836 Hashimoto thyroiditis Diseases 0.000 description 2
• 101001018145 Homo sapiens Mitogen-activated protein kinase kinase kinase 3 Proteins 0.000 description 2
• MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
• 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
• 208000016300 Idiopathic chronic eosinophilic pneumonia Diseases 0.000 description 2
• 102100032817 Integrin alpha-5 Human genes 0.000 description 2
• 108010041014 Integrin alpha5 Proteins 0.000 description 2
• 108010042918 Integrin alpha5beta1 Proteins 0.000 description 2
• 102000019223 Interleukin-1 receptor Human genes 0.000 description 2
• 108050006617 Interleukin-1 receptor Proteins 0.000 description 2
• 108060001621 Isoprenylcysteine carboxyl methyltransferase Proteins 0.000 description 2
• UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 2
• 102000003680 Leukotriene B4 receptors Human genes 0.000 description 2
• 108090000093 Leukotriene B4 receptors Proteins 0.000 description 2
• 102100037611 Lysophospholipase Human genes 0.000 description 2
• 108010068355 MAP Kinase Kinase 3 Proteins 0.000 description 2
• 108010068304 MAP Kinase Kinase 4 Proteins 0.000 description 2
• 108010068339 MAP Kinase Kinase 7 Proteins 0.000 description 2
• 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
• 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
• 102000009073 Macrophage Migration-Inhibitory Factors Human genes 0.000 description 2
• 108010048043 Macrophage Migration-Inhibitory Factors Proteins 0.000 description 2
• TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
• CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
• 229930195725 Mannitol Natural products 0.000 description 2
• 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
• 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
• 102100030219 Matrix metalloproteinase-17 Human genes 0.000 description 2
• 108090000585 Matrix metalloproteinase-17 Proteins 0.000 description 2
• 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 2
• 102100036834 Metabotropic glutamate receptor 1 Human genes 0.000 description 2
• 101710086716 Metabotropic glutamate receptor 1 Proteins 0.000 description 2
• 102100023174 Methionine aminopeptidase 2 Human genes 0.000 description 2
• 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 2
• 102100026929 Mitogen-activated protein kinase 11 Human genes 0.000 description 2
• 102100026932 Mitogen-activated protein kinase 12 Human genes 0.000 description 2
• 102100026930 Mitogen-activated protein kinase 13 Human genes 0.000 description 2
• 108700015928 Mitogen-activated protein kinase 13 Proteins 0.000 description 2
• 102100023482 Mitogen-activated protein kinase 14 Human genes 0.000 description 2
• 102100037808 Mitogen-activated protein kinase 8 Human genes 0.000 description 2
• 101710164337 Mitogen-activated protein kinase kinase kinase 5 Proteins 0.000 description 2
• 102100026907 Mitogen-activated protein kinase kinase kinase 8 Human genes 0.000 description 2
• 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 2
• MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
• CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 2
• 108090000028 Neprilysin Proteins 0.000 description 2
• 102000003729 Neprilysin Human genes 0.000 description 2
• 108010040716 Neurokinin-3 Receptors Proteins 0.000 description 2
• 102100029409 Neuromedin-K receptor Human genes 0.000 description 2
• 102000008299 Nitric Oxide Synthase Human genes 0.000 description 2
• 108010021487 Nitric Oxide Synthase Proteins 0.000 description 2
• 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 2
• 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 2
• 108010049586 Norepinephrine Plasma Membrane Transport Proteins Proteins 0.000 description 2
• PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 2
• 108020005497 Nuclear hormone receptor Proteins 0.000 description 2
• CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
• 206010061876 Obstruction Diseases 0.000 description 2
• 102100037602 P2X purinoceptor 7 Human genes 0.000 description 2
• 101710189965 P2X purinoceptor 7 Proteins 0.000 description 2
• AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 2
• 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
• 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
• 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 2
• 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 2
• 102100039277 Pleiotrophin Human genes 0.000 description 2
• 208000003971 Posterior uveitis Diseases 0.000 description 2
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
• XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
• 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 2
• 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 2
• 108700039882 Protein Glutamine gamma Glutamyltransferase 2 Proteins 0.000 description 2
• 108091008611 Protein Kinase B Proteins 0.000 description 2
• 102100038095 Protein-glutamine gamma-glutamyltransferase 2 Human genes 0.000 description 2
• 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 2
• 108090000783 Renin Proteins 0.000 description 2
• 102100028255 Renin Human genes 0.000 description 2
• 102100024735 Resistin Human genes 0.000 description 2
• 108010047909 Resistin Proteins 0.000 description 2
• 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
• 206010039085 Rhinitis allergic Diseases 0.000 description 2
• YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
• 206010039710 Scleroderma Diseases 0.000 description 2
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
• 102100033929 Sodium-dependent noradrenaline transporter Human genes 0.000 description 2
• 102100028874 Sodium-dependent serotonin transporter Human genes 0.000 description 2
• 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 description 2
• 102100030416 Stromelysin-1 Human genes 0.000 description 2
• 229930006000 Sucrose Natural products 0.000 description 2
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
• 102000003141 Tachykinin Human genes 0.000 description 2
• 102000002262 Thromboplastin Human genes 0.000 description 2
• 108010000499 Thromboplastin Proteins 0.000 description 2
• 102000004243 Tubulin Human genes 0.000 description 2
• 108090000704 Tubulin Proteins 0.000 description 2
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
• 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 2
• 102100029823 Tyrosine-protein kinase BTK Human genes 0.000 description 2
• 102100031358 Urokinase-type plasminogen activator Human genes 0.000 description 2
• TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
• 229940022698 acetylcholinesterase Drugs 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 239000002465 adenosine A2a receptor agonist Substances 0.000 description 2
• 239000002671 adjuvant Substances 0.000 description 2
• 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
• 108010003059 aggrecanase Proteins 0.000 description 2
• 229960002459 alefacept Drugs 0.000 description 2
• 201000009961 allergic asthma Diseases 0.000 description 2
• 201000010105 allergic rhinitis Diseases 0.000 description 2
• 229960000836 amitriptyline Drugs 0.000 description 2
• KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 2
• 208000007502 anemia Diseases 0.000 description 2
• 239000003242 anti bacterial agent Substances 0.000 description 2
• 229940088710 antibiotic agent Drugs 0.000 description 2
• 239000008346 aqueous phase Substances 0.000 description 2
• 239000007864 aqueous solution Substances 0.000 description 2
• 125000004429 atom Chemical group 0.000 description 2
• 208000010668 atopic eczema Diseases 0.000 description 2
• LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
• 229960002170 azathioprine Drugs 0.000 description 2
• BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
• 239000002439 beta secretase inhibitor Substances 0.000 description 2
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
• 230000037396 body weight Effects 0.000 description 2
• 238000009835 boiling Methods 0.000 description 2
• 239000012888 bovine serum Substances 0.000 description 2
• 229960004015 calcitonin Drugs 0.000 description 2
• BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
• 229910052799 carbon Inorganic materials 0.000 description 2
• 239000001768 carboxy methyl cellulose Substances 0.000 description 2
• 210000000845 cartilage Anatomy 0.000 description 2
• 210000002421 cell wall Anatomy 0.000 description 2
• 230000008859 change Effects 0.000 description 2
• 239000000812 cholinergic antagonist Substances 0.000 description 2
• 208000019069 chronic childhood arthritis Diseases 0.000 description 2
• 201000009323 chronic eosinophilic pneumonia Diseases 0.000 description 2
• 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 2
• MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
• 230000000295 complement effect Effects 0.000 description 2
• 238000007796 conventional method Methods 0.000 description 2
• JURKNVYFZMSNLP-UHFFFAOYSA-N cyclobenzaprine Chemical compound C1=CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 JURKNVYFZMSNLP-UHFFFAOYSA-N 0.000 description 2
• 229960003572 cyclobenzaprine Drugs 0.000 description 2
• 238000011161 development Methods 0.000 description 2
• 230000018109 developmental process Effects 0.000 description 2
• 229960003957 dexamethasone Drugs 0.000 description 2
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
• 239000010432 diamond Substances 0.000 description 2
• XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 2
• 238000010790 dilution Methods 0.000 description 2
• 239000012895 dilution Substances 0.000 description 2
• SLPJGDQJLTYWCI-UHFFFAOYSA-N dimethyl-(4,5,6,7-tetrabromo-1h-benzoimidazol-2-yl)-amine Chemical compound BrC1=C(Br)C(Br)=C2NC(N(C)C)=NC2=C1Br SLPJGDQJLTYWCI-UHFFFAOYSA-N 0.000 description 2
• 229960002768 dipyridamole Drugs 0.000 description 2
• IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 2
• 208000035475 disorder Diseases 0.000 description 2
• 229960005426 doxepin Drugs 0.000 description 2
• ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 2
• 238000002651 drug therapy Methods 0.000 description 2
• 239000000428 dust Substances 0.000 description 2
• 229960000284 efalizumab Drugs 0.000 description 2
• 238000005516 engineering process Methods 0.000 description 2
• 239000003623 enhancer Substances 0.000 description 2
• 230000007613 environmental effect Effects 0.000 description 2
• 229940088598 enzyme Drugs 0.000 description 2
• 229940105423 erythropoietin Drugs 0.000 description 2
• 108010038795 estrogen receptors Proteins 0.000 description 2
• 229960004945 etoricoxib Drugs 0.000 description 2
• MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 description 2
• 208000024711 extrinsic asthma Diseases 0.000 description 2
• 239000010408 film Substances 0.000 description 2
• 238000001914 filtration Methods 0.000 description 2
• 210000003811 finger Anatomy 0.000 description 2
• 239000000796 flavoring agent Substances 0.000 description 2
• 229960002464 fluoxetine Drugs 0.000 description 2
• 239000012634 fragment Substances 0.000 description 2
• 230000002496 gastric effect Effects 0.000 description 2
• 239000000499 gel Substances 0.000 description 2
• FVIZARNDLVOMSU-UHFFFAOYSA-N ginsenoside K Natural products C1CC(C2(CCC3C(C)(C)C(O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O FVIZARNDLVOMSU-UHFFFAOYSA-N 0.000 description 2
• 229960001031 glucose Drugs 0.000 description 2
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
• 235000011187 glycerol Nutrition 0.000 description 2
• 230000012010 growth Effects 0.000 description 2
• 239000003102 growth factor Substances 0.000 description 2
• 239000007902 hard capsule Substances 0.000 description 2
• 108091008039 hormone receptors Proteins 0.000 description 2
• OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 2
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
• 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
• 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
• BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 2
• 229960004801 imipramine Drugs 0.000 description 2
• 239000003018 immunosuppressive agent Substances 0.000 description 2
• 238000011534 incubation Methods 0.000 description 2
• 210000004969 inflammatory cell Anatomy 0.000 description 2
• 229960000598 infliximab Drugs 0.000 description 2
• 238000001802 infusion Methods 0.000 description 2
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
• 210000004347 intestinal mucosa Anatomy 0.000 description 2
• 238000007912 intraperitoneal administration Methods 0.000 description 2
• 239000007928 intraperitoneal injection Substances 0.000 description 2
• 150000002500 ions Chemical class 0.000 description 2
• 230000002427 irreversible effect Effects 0.000 description 2
• 208000002551 irritable bowel syndrome Diseases 0.000 description 2
• 230000000366 juvenile effect Effects 0.000 description 2
• 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 2
• 210000003127 knee Anatomy 0.000 description 2
• 208000032839 leukemia Diseases 0.000 description 2
• 150000002617 leukotrienes Chemical class 0.000 description 2
• YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 2
• 210000004072 lung Anatomy 0.000 description 2
• 230000003211 malignant effect Effects 0.000 description 2
• 239000000594 mannitol Substances 0.000 description 2
• 235000010355 mannitol Nutrition 0.000 description 2
• 229960001855 mannitol Drugs 0.000 description 2
• HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
• OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
• 108010085212 mitogen and stress-activated protein kinase 1 Proteins 0.000 description 2
• 238000002156 mixing Methods 0.000 description 2
• BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
• 210000003205 muscle Anatomy 0.000 description 2
• 229940035363 muscle relaxants Drugs 0.000 description 2
• 239000003158 myorelaxant agent Substances 0.000 description 2
• 239000002105 nanoparticle Substances 0.000 description 2
• 229960002009 naproxen Drugs 0.000 description 2
• CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 2
• 239000013642 negative control Substances 0.000 description 2
• 231100000252 nontoxic Toxicity 0.000 description 2
• 230000003000 nontoxic effect Effects 0.000 description 2
• 229960002748 norepinephrine Drugs 0.000 description 2
• SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
• 229960001158 nortriptyline Drugs 0.000 description 2
• 102000006255 nuclear receptors Human genes 0.000 description 2
• 108020004017 nuclear receptors Proteins 0.000 description 2
• 208000007892 occupational asthma Diseases 0.000 description 2
• 239000012044 organic layer Substances 0.000 description 2
• 238000002638 palliative care Methods 0.000 description 2
• 229960002296 paroxetine Drugs 0.000 description 2
• 239000002245 particle Substances 0.000 description 2
• 230000001991 pathophysiological effect Effects 0.000 description 2
• 230000035699 permeability Effects 0.000 description 2
• 210000002824 peroxisome Anatomy 0.000 description 2
• 235000019271 petrolatum Nutrition 0.000 description 2
• 238000001126 phototherapy Methods 0.000 description 2
• 230000036470 plasma concentration Effects 0.000 description 2
• 230000010287 polarization Effects 0.000 description 2
• 229920001184 polypeptide Polymers 0.000 description 2
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
• 210000003240 portal vein Anatomy 0.000 description 2
• OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
• 239000002244 precipitate Substances 0.000 description 2
• 238000001556 precipitation Methods 0.000 description 2
• 239000002243 precursor Substances 0.000 description 2
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
• 230000000750 progressive effect Effects 0.000 description 2
• 230000035755 proliferation Effects 0.000 description 2
• 239000003380 propellant Substances 0.000 description 2
• 235000019833 protease Nutrition 0.000 description 2
• 125000006239 protecting group Chemical group 0.000 description 2
• 102000029740 protein-S-isoprenylcysteine O-methyltransferase Human genes 0.000 description 2
• 208000002815 pulmonary hypertension Diseases 0.000 description 2
• 230000002285 radioactive effect Effects 0.000 description 2
• 208000002574 reactive arthritis Diseases 0.000 description 2
• 229960003770 reboxetine Drugs 0.000 description 2
• 230000002829 reductive effect Effects 0.000 description 2
• 238000010992 reflux Methods 0.000 description 2
• 208000008742 seborrheic dermatitis Diseases 0.000 description 2
• 230000001624 sedative effect Effects 0.000 description 2
• 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 2
• 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 2
• 229940076279 serotonin Drugs 0.000 description 2
• 108010049619 serotonin 7 receptor Proteins 0.000 description 2
• 206010040400 serum sickness Diseases 0.000 description 2
• 208000013220 shortness of breath Diseases 0.000 description 2
• BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 2
• 238000010898 silica gel chromatography Methods 0.000 description 2
• 235000017557 sodium bicarbonate Nutrition 0.000 description 2
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
• 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
• 239000007901 soft capsule Substances 0.000 description 2
• 239000000600 sorbitol Substances 0.000 description 2
• 235000010356 sorbitol Nutrition 0.000 description 2
• 238000004611 spectroscopical analysis Methods 0.000 description 2
• 108010035597 sphingosine kinase Proteins 0.000 description 2
• 230000000638 stimulation Effects 0.000 description 2
• 239000005720 sucrose Substances 0.000 description 2
• 235000000346 sugar Nutrition 0.000 description 2
• 229960001940 sulfasalazine Drugs 0.000 description 2
• NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 2
• NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 2
• 239000006228 supernatant Substances 0.000 description 2
• 208000024891 symptom Diseases 0.000 description 2
• 238000003786 synthesis reaction Methods 0.000 description 2
• 108060008037 tachykinin Proteins 0.000 description 2
• 229940095064 tartrate Drugs 0.000 description 2
• ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
• 229940124597 therapeutic agent Drugs 0.000 description 2
• 229940126585 therapeutic drug Drugs 0.000 description 2
• 238000002560 therapeutic procedure Methods 0.000 description 2
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
• 229940088594 vitamin Drugs 0.000 description 2
• 239000011782 vitamin Substances 0.000 description 2
• 235000013343 vitamin Nutrition 0.000 description 2
• 229930003231 vitamin Natural products 0.000 description 2
• 150000003722 vitamin derivatives Chemical class 0.000 description 2
• 239000011534 wash buffer Substances 0.000 description 2
• 210000000707 wrist Anatomy 0.000 description 2
• 239000008096 xylene Substances 0.000 description 2
• 239000000811 xylitol Substances 0.000 description 2
• 229960002675 xylitol Drugs 0.000 description 2
• 235000010447 xylitol Nutrition 0.000 description 2
• HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
• HDTRYLNUVZCQOY-UHFFFAOYSA-N &alpha;-D-glucopyranosyl-&alpha;-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
• NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
• PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
• PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
• KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
• LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
• ARLKVQYMFRECLV-JSGCOSHPSA-N (2s)-2-[[(2s)-2-amino-3-(1h-indol-3-yl)propanoyl]amino]-4-methylsulfanylbutanamide Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CCSC)C(N)=O)=CNC2=C1 ARLKVQYMFRECLV-JSGCOSHPSA-N 0.000 description 1
• CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 1
• GLUJNGJDHCTUJY-YFKPBYRVSA-N (3S)-beta-leucine Chemical compound CC(C)[C@@H](N)CC(O)=O GLUJNGJDHCTUJY-YFKPBYRVSA-N 0.000 description 1
• UXKQLDYBPWULKJ-BPUTZDHNSA-N (3s)-4-amino-3-[[(2s)-2-[[(2s)-2-amino-3-(1h-indol-3-yl)propanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-oxobutanoic acid Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(N)=O)=CNC2=C1 UXKQLDYBPWULKJ-BPUTZDHNSA-N 0.000 description 1
• 125000005859 (C1-C6)alkanoyloxymethyl group Chemical group 0.000 description 1
• WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
• DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
• ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 1
• ZKMNUMMKYBVTFN-HNNXBMFYSA-N (S)-ropivacaine Chemical compound CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C ZKMNUMMKYBVTFN-HNNXBMFYSA-N 0.000 description 1
• XGWIJUOSCAQSSV-XHDPSFHLSA-N (S,S)-hexythiazox Chemical compound S([C@H]([C@@H]1C)C=2C=CC(Cl)=CC=2)C(=O)N1C(=O)NC1CCCCC1 XGWIJUOSCAQSSV-XHDPSFHLSA-N 0.000 description 1
• YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 1
• LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
• KMNLXCBYBKHKSK-UHFFFAOYSA-N 1-[4-hydroxy-3-[(4-phenylphenyl)methyl]-3,4-dihydro-2h-chromen-7-yl]cyclopentane-1-carboxylic acid Chemical compound C1OC2=CC(C3(CCCC3)C(O)=O)=CC=C2C(O)C1CC(C=C1)=CC=C1C1=CC=CC=C1 KMNLXCBYBKHKSK-UHFFFAOYSA-N 0.000 description 1
• OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
• 102100036506 11-beta-hydroxysteroid dehydrogenase 1 Human genes 0.000 description 1
• 101710186107 11-beta-hydroxysteroid dehydrogenase 1 Proteins 0.000 description 1
• RVCKCEDKBVEEHL-UHFFFAOYSA-N 2,3,4,5,6-pentachlorobenzyl alcohol Chemical compound OCC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl RVCKCEDKBVEEHL-UHFFFAOYSA-N 0.000 description 1
• ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
• HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
• IRMTXMJNHRISQH-UHFFFAOYSA-N 2-[2-[2-(diaminomethylideneamino)ethyldisulfanyl]ethyl]guanidine Chemical compound NC(N)=NCCSSCCN=C(N)N IRMTXMJNHRISQH-UHFFFAOYSA-N 0.000 description 1
• AUZUGWXLBGZUPP-GXDHUFHOSA-N 2-[4-[(e)-(2-oxocyclohexylidene)methyl]phenyl]propanoic acid Chemical compound C1=CC(C(C(O)=O)C)=CC=C1\C=C/1C(=O)CCCC\1 AUZUGWXLBGZUPP-GXDHUFHOSA-N 0.000 description 1
• VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 1
• PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 1
• XCHHJFVNQPPLJK-UHFFFAOYSA-N 2-carboxyphenolate;1h-imidazol-1-ium Chemical compound C1=CNC=N1.OC(=O)C1=CC=CC=C1O XCHHJFVNQPPLJK-UHFFFAOYSA-N 0.000 description 1
• VWFJDQUYCIWHTN-YFVJMOTDSA-N 2-trans,6-trans-farnesyl diphosphate Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CO[P@](O)(=O)OP(O)(O)=O VWFJDQUYCIWHTN-YFVJMOTDSA-N 0.000 description 1
• LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
• MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 description 1
• VNEOHNUYPRAJMX-UHFFFAOYSA-N 3-[[2-[[2-amino-3-(1h-indol-3-yl)propanoyl]amino]-4-methylpentanoyl]amino]-4-[[1-(butoxycarbonylamino)-1-oxo-3-phenylpropan-2-yl]amino]-4-oxobutanoic acid Chemical compound C=1NC2=CC=CC=C2C=1CC(N)C(=O)NC(CC(C)C)C(=O)NC(CC(O)=O)C(=O)NC(C(=O)NC(=O)OCCCC)CC1=CC=CC=C1 VNEOHNUYPRAJMX-UHFFFAOYSA-N 0.000 description 1
• IJVCSMSMFSCRME-UHFFFAOYSA-N 3-methyl-2,4,4a,5,6,7,7a,13-octahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol Chemical compound C12CCC(O)C3OC4=C5C32CCN(C)C1CC5=CC=C4O IJVCSMSMFSCRME-UHFFFAOYSA-N 0.000 description 1
• 102000001779 3-oxo-5-alpha-steroid 4-dehydrogenase Human genes 0.000 description 1
• 108010029908 3-oxo-5-alpha-steroid 4-dehydrogenase Proteins 0.000 description 1
• TYNLGDBUJLVSMA-UHFFFAOYSA-N 4,5-diacetyloxy-9,10-dioxo-2-anthracenecarboxylic acid Chemical compound O=C1C2=CC(C(O)=O)=CC(OC(C)=O)=C2C(=O)C2=C1C=CC=C2OC(=O)C TYNLGDBUJLVSMA-UHFFFAOYSA-N 0.000 description 1
• 108091000044 4-hydroxy-tetrahydrodipicolinate synthase Proteins 0.000 description 1
• OOXNYFKPOPJIOT-UHFFFAOYSA-N 5-(3-bromophenyl)-7-(6-morpholin-4-ylpyridin-3-yl)pyrido[2,3-d]pyrimidin-4-amine;dihydrochloride Chemical compound Cl.Cl.C=12C(N)=NC=NC2=NC(C=2C=NC(=CC=2)N2CCOCC2)=CC=1C1=CC=CC(Br)=C1 OOXNYFKPOPJIOT-UHFFFAOYSA-N 0.000 description 1
• 102000035038 5-HT1 receptors Human genes 0.000 description 1
• 108091005478 5-HT1 receptors Proteins 0.000 description 1
• 102000056834 5-HT2 Serotonin Receptors Human genes 0.000 description 1
• 108091005479 5-HT2 receptors Proteins 0.000 description 1
• 102000049773 5-HT2A Serotonin Receptor Human genes 0.000 description 1
• 108010072584 5-HT2B Serotonin Receptor Proteins 0.000 description 1
• 108091005477 5-HT3 receptors Proteins 0.000 description 1
• 102000035037 5-HT3 receptors Human genes 0.000 description 1
• 108050002825 5-Hydroxytryptamine 1A receptors Proteins 0.000 description 1
• 102000010185 5-Hydroxytryptamine 2B receptors Human genes 0.000 description 1
• 108050009686 5-Hydroxytryptamine 5A receptors Proteins 0.000 description 1
• 102000001472 5-Hydroxytryptamine 5A receptors Human genes 0.000 description 1
• 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 description 1
• 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
• 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
• XZGLNCKSNVGDNX-UHFFFAOYSA-N 5-methyl-2h-tetrazole Chemical compound CC=1N=NNN=1 XZGLNCKSNVGDNX-UHFFFAOYSA-N 0.000 description 1
• NVOYVOBDTVTBDX-AGUVMIOSSA-N 8g15t83e6i Chemical class C1([C@@H](CO)C(=O)OC2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)CC)=CC=CC=C1 NVOYVOBDTVTBDX-AGUVMIOSSA-N 0.000 description 1
• QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
• 102100027400 A disintegrin and metalloproteinase with thrombospondin motifs 4 Human genes 0.000 description 1
• 108091005664 ADAMTS4 Proteins 0.000 description 1
• 102000051389 ADAMTS5 Human genes 0.000 description 1
• 108091005663 ADAMTS5 Proteins 0.000 description 1
• 102000006267 AMP Deaminase Human genes 0.000 description 1
• 108700016228 AMP deaminases Proteins 0.000 description 1
• 102000003678 AMPA Receptors Human genes 0.000 description 1
• 108090000078 AMPA Receptors Proteins 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 102000007471 Adenosine A2A receptor Human genes 0.000 description 1
• 108010085277 Adenosine A2A receptor Proteins 0.000 description 1
• 108010060261 Adenosine A3 Receptor Proteins 0.000 description 1
• 102000008161 Adenosine A3 Receptor Human genes 0.000 description 1
• 102100032534 Adenosine kinase Human genes 0.000 description 1
• 108010076278 Adenosine kinase Proteins 0.000 description 1
• 208000005676 Adrenogenital syndrome Diseases 0.000 description 1
• 102400001318 Adrenomedullin Human genes 0.000 description 1
• 101800004616 Adrenomedullin Proteins 0.000 description 1
• 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 description 1
• 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
• 206010027654 Allergic conditions Diseases 0.000 description 1
• 201000004384 Alopecia Diseases 0.000 description 1
• 102100035991 Alpha-2-antiplasmin Human genes 0.000 description 1
• 206010001889 Alveolitis Diseases 0.000 description 1
• 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 1
• 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 1
• 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
• 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
• 241001465677 Ancylostomatoidea Species 0.000 description 1
• 102000009840 Angiopoietins Human genes 0.000 description 1
• 108010009906 Angiopoietins Proteins 0.000 description 1
• 102000004881 Angiotensinogen Human genes 0.000 description 1
• 108090001067 Angiotensinogen Proteins 0.000 description 1
• 101100327398 Anopheles gambiae CecA gene Proteins 0.000 description 1
• 206010002965 Aplasia pure red cell Diseases 0.000 description 1
• 208000032467 Aplastic anaemia Diseases 0.000 description 1
• 229940088872 Apoptosis inhibitor Drugs 0.000 description 1
• 102000014654 Aromatase Human genes 0.000 description 1
• 108010078554 Aromatase Proteins 0.000 description 1
• 206010003210 Arteriosclerosis Diseases 0.000 description 1
• 208000006820 Arthralgia Diseases 0.000 description 1
• 102100034193 Aspartate aminotransferase, mitochondrial Human genes 0.000 description 1
• 206010003594 Ataxia telangiectasia Diseases 0.000 description 1
• 201000001320 Atherosclerosis Diseases 0.000 description 1
• 101150065175 Atm gene Proteins 0.000 description 1
• 208000023275 Autoimmune disease Diseases 0.000 description 1
• 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 description 1
• 208000037157 Azotemia Diseases 0.000 description 1
• 102100028520 B1 bradykinin receptor Human genes 0.000 description 1
• 108060003359 BDKRB1 Proteins 0.000 description 1
• 241000193830 Bacillus <bacterium> Species 0.000 description 1
• 108010077805 Bacterial Proteins Proteins 0.000 description 1
• 208000035143 Bacterial infection Diseases 0.000 description 1
• KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 1
• 208000027496 Behcet disease Diseases 0.000 description 1
• 208000009137 Behcet syndrome Diseases 0.000 description 1
• 239000005711 Benzoic acid Substances 0.000 description 1
• 206010004485 Berylliosis Diseases 0.000 description 1
• 102100039705 Beta-2 adrenergic receptor Human genes 0.000 description 1
• 102100034159 Beta-3 adrenergic receptor Human genes 0.000 description 1
• 102100023995 Beta-nerve growth factor Human genes 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
• MNIPYSSQXLZQLJ-UHFFFAOYSA-N Biofenac Chemical compound OC(=O)COC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl MNIPYSSQXLZQLJ-UHFFFAOYSA-N 0.000 description 1
• BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
• 206010006482 Bronchospasm Diseases 0.000 description 1
• VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
• 102100021942 C-C motif chemokine 28 Human genes 0.000 description 1
• 102100032528 C-type lectin domain family 11 member A Human genes 0.000 description 1
• 101710167766 C-type lectin domain family 11 member A Proteins 0.000 description 1
• 102100021703 C3a anaphylatoxin chemotactic receptor Human genes 0.000 description 1
• 108050000222 C3a anaphylatoxin chemotactic receptors Proteins 0.000 description 1
• 108091005932 CCKBR Proteins 0.000 description 1
• 102100031168 CCN family member 2 Human genes 0.000 description 1
• 102000053028 CD36 Antigens Human genes 0.000 description 1
• 108010045374 CD36 Antigens Proteins 0.000 description 1
• 108010034798 CDC2 Protein Kinase Proteins 0.000 description 1
• 229940124638 COX inhibitor Drugs 0.000 description 1
• LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 description 1
• 101001082567 Caenorhabditis elegans Hypoxia-inducible factor 1 Proteins 0.000 description 1
• 108090000312 Calcium Channels Proteins 0.000 description 1
• 102000003922 Calcium Channels Human genes 0.000 description 1
• UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
• 102000005702 Calcium-Activated Potassium Channels Human genes 0.000 description 1
• 108010045489 Calcium-Activated Potassium Channels Proteins 0.000 description 1
• 102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
• 108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
• 102000004657 Calcium-Calmodulin-Dependent Protein Kinase Type 2 Human genes 0.000 description 1
• 108010003721 Calcium-Calmodulin-Dependent Protein Kinase Type 2 Proteins 0.000 description 1
• 102000000584 Calmodulin Human genes 0.000 description 1
• 108010041952 Calmodulin Proteins 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
• 102000004031 Carboxy-Lyases Human genes 0.000 description 1
• 108090000489 Carboxy-Lyases Proteins 0.000 description 1
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
• 102000003847 Carboxypeptidase B2 Human genes 0.000 description 1
• 108090000201 Carboxypeptidase B2 Proteins 0.000 description 1
• 102000008122 Casein Kinase I Human genes 0.000 description 1
• 108010049812 Casein Kinase I Proteins 0.000 description 1
• 101000658635 Catharanthus roseus Tabersonine synthase Proteins 0.000 description 1
• 101710089440 Cathepsin 8 Proteins 0.000 description 1
• 102000004171 Cathepsin K Human genes 0.000 description 1
• 108090000625 Cathepsin K Proteins 0.000 description 1
• 101100321770 Cavia porcellus 5HT1E gene Proteins 0.000 description 1
• PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
• 101100059601 Ceratitis capitata CEC1 gene Proteins 0.000 description 1
• 229920001661 Chitosan Polymers 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
• 102400000884 Cholecystokinin-5 Human genes 0.000 description 1
• 101800001545 Cholecystokinin-5 Proteins 0.000 description 1
• 102400000887 Cholecystokinin-7 Human genes 0.000 description 1
• 101800001542 Cholecystokinin-7 Proteins 0.000 description 1
• 102000003914 Cholinesterases Human genes 0.000 description 1
• 108090000322 Cholinesterases Proteins 0.000 description 1
• 208000000668 Chronic Pancreatitis Diseases 0.000 description 1
• 208000023355 Chronic beryllium disease Diseases 0.000 description 1
• 241000723346 Cinnamomum camphora Species 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• PJRGDZVSIIYGOA-UHFFFAOYSA-N ClC=1C=C(CNCCC2=CC=C(C=C2)C2=C(SC=C2)C(=N)N)C=CC=1 Chemical compound ClC=1C=C(CNCCC2=CC=C(C=C2)C2=C(SC=C2)C(=N)N)C=CC=1 PJRGDZVSIIYGOA-UHFFFAOYSA-N 0.000 description 1
• 102100023804 Coagulation factor VII Human genes 0.000 description 1
• 101000973921 Coccidioides posadasii (strain C735) Neutral protease 2 homolog MEP8 Proteins 0.000 description 1
• 108010035532 Collagen Proteins 0.000 description 1
• 102000008186 Collagen Human genes 0.000 description 1
• 208000027932 Collagen disease Diseases 0.000 description 1
• 108050005238 Collagenase 3 Proteins 0.000 description 1
• 108010003384 Colony-Stimulating Factor Receptors Proteins 0.000 description 1
• 102000004626 Colony-Stimulating Factor Receptors Human genes 0.000 description 1
• 102100031506 Complement C5 Human genes 0.000 description 1
• 108010028773 Complement C5 Proteins 0.000 description 1
• 208000032170 Congenital Abnormalities Diseases 0.000 description 1
• 208000008448 Congenital adrenal hyperplasia Diseases 0.000 description 1
• 206010010356 Congenital anomaly Diseases 0.000 description 1
• 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
• 108010039419 Connective Tissue Growth Factor Proteins 0.000 description 1
• 102000008064 Corticotropin Receptors Human genes 0.000 description 1
• 108010074311 Corticotropin Receptors Proteins 0.000 description 1
• 229920002785 Croscarmellose sodium Polymers 0.000 description 1
• 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 1
• 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
• 102100032857 Cyclin-dependent kinase 1 Human genes 0.000 description 1
• 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 1
• 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 1
• 229920000858 Cyclodextrin Polymers 0.000 description 1
• 108010072220 Cyclophilin A Proteins 0.000 description 1
• 108010068682 Cyclophilins Proteins 0.000 description 1
• 102000001493 Cyclophilins Human genes 0.000 description 1
• 229930105110 Cyclosporin A Natural products 0.000 description 1
• 108010005843 Cysteine Proteases Proteins 0.000 description 1
• 102000005927 Cysteine Proteases Human genes 0.000 description 1
• 102000010918 Cysteinyl leukotriene receptors Human genes 0.000 description 1
• 108050001116 Cysteinyl leukotriene receptors Proteins 0.000 description 1
• 108091000069 Cystinyl Aminopeptidase Proteins 0.000 description 1
• 102000030900 Cystinyl aminopeptidase Human genes 0.000 description 1
• 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 description 1
• 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 1
• 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
• 102000003849 Cytochrome P450 Human genes 0.000 description 1
• RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
• AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
• NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
• 108010041052 DNA Topoisomerase IV Proteins 0.000 description 1
• 108090000323 DNA Topoisomerases Proteins 0.000 description 1
• 102000003915 DNA Topoisomerases Human genes 0.000 description 1
• 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
• 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
• 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
• 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
• 102100031817 Delta-type opioid receptor Human genes 0.000 description 1
• 101710121791 Delta-type opioid receptor Proteins 0.000 description 1
• 206010012438 Dermatitis atopic Diseases 0.000 description 1
• 206010012455 Dermatitis exfoliative Diseases 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• 101001098806 Dictyostelium discoideum cGMP-specific 3',5'-cGMP phosphodiesterase 3 Proteins 0.000 description 1
• 108090000204 Dipeptidase 1 Proteins 0.000 description 1
• 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 1
• 108010043648 Discoidin Domain Receptors Proteins 0.000 description 1
• 102000002706 Discoidin Domain Receptors Human genes 0.000 description 1
• 101800001224 Disintegrin Proteins 0.000 description 1
• 108010015720 Dopamine beta-Hydroxylase Proteins 0.000 description 1
• 102100033156 Dopamine beta-hydroxylase Human genes 0.000 description 1
• 206010013700 Drug hypersensitivity Diseases 0.000 description 1
• 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
• 206010013774 Dry eye Diseases 0.000 description 1
• 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 1
• 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 description 1
• 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
• 206010013883 Dwarfism Diseases 0.000 description 1
• 102100028890 E3 ubiquitin-protein ligase synoviolin Human genes 0.000 description 1
• 102000001301 EGF receptor Human genes 0.000 description 1
• 108060006698 EGF receptor Proteins 0.000 description 1
• 208000017701 Endocrine disease Diseases 0.000 description 1
• 102100037241 Endoglin Human genes 0.000 description 1
• 108010036395 Endoglin Proteins 0.000 description 1
• 108010042407 Endonucleases Proteins 0.000 description 1
• 102000005593 Endopeptidases Human genes 0.000 description 1
• 108010059378 Endopeptidases Proteins 0.000 description 1
• 102100030011 Endoribonuclease Human genes 0.000 description 1
• 101710199605 Endoribonuclease Proteins 0.000 description 1
• 108010090549 Endothelin A Receptor Proteins 0.000 description 1
• 102100040630 Endothelin-1 receptor Human genes 0.000 description 1
• 102100029113 Endothelin-converting enzyme 2 Human genes 0.000 description 1
• 101710144982 Endothelin-converting enzyme 2 Proteins 0.000 description 1
• 108010055325 EphB3 Receptor Proteins 0.000 description 1
• 108020002908 Epoxide hydrolase Proteins 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• 206010015150 Erythema Diseases 0.000 description 1
• 206010015218 Erythema multiforme Diseases 0.000 description 1
• 108010075944 Erythropoietin Receptors Proteins 0.000 description 1
• 102100036509 Erythropoietin receptor Human genes 0.000 description 1
• 108010007005 Estrogen Receptor alpha Proteins 0.000 description 1
• 244000166102 Eucalyptus leucoxylon Species 0.000 description 1
• 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 1
• 101710116650 FAD-dependent monooxygenase Proteins 0.000 description 1
• 108010023321 Factor VII Proteins 0.000 description 1
• VWFJDQUYCIWHTN-UHFFFAOYSA-N Farnesyl pyrophosphate Natural products CC(C)=CCCC(C)=CCCC(C)=CCOP(O)(=O)OP(O)(O)=O VWFJDQUYCIWHTN-UHFFFAOYSA-N 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 206010051011 Fibrinous bronchitis Diseases 0.000 description 1
• 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
• 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
• 208000001640 Fibromyalgia Diseases 0.000 description 1
• 108010091820 Focal Adhesion Kinase 2 Proteins 0.000 description 1
• 102000016621 Focal Adhesion Protein-Tyrosine Kinases Human genes 0.000 description 1
• 108010067715 Focal Adhesion Protein-Tyrosine Kinases Proteins 0.000 description 1
• BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
• 229930091371 Fructose Natural products 0.000 description 1
• 239000005715 Fructose Substances 0.000 description 1
• RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
• 102000004300 GABA-A Receptors Human genes 0.000 description 1
• 108090000839 GABA-A Receptors Proteins 0.000 description 1
• 102100040837 Galactoside alpha-(1,2)-fucosyltransferase 2 Human genes 0.000 description 1
• 102000030902 Galactosyltransferase Human genes 0.000 description 1
• 108060003306 Galactosyltransferase Proteins 0.000 description 1
• 241000287828 Gallus gallus Species 0.000 description 1
• 102100021023 Gamma-glutamyl hydrolase Human genes 0.000 description 1
• 208000007882 Gastritis Diseases 0.000 description 1
• 208000018522 Gastrointestinal disease Diseases 0.000 description 1
• 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
• 101800001586 Ghrelin Proteins 0.000 description 1
• 102400000442 Ghrelin-28 Human genes 0.000 description 1
• 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 1
• 206010018364 Glomerulonephritis Diseases 0.000 description 1
• 102000006419 Glucagon-Like Peptide Receptors Human genes 0.000 description 1
• 108010083749 Glucagon-Like Peptide Receptors Proteins 0.000 description 1
• 102100031132 Glucose-6-phosphate isomerase Human genes 0.000 description 1
• 102000005731 Glucose-6-phosphate isomerase Human genes 0.000 description 1
• 108010027915 Glutamate Receptors Proteins 0.000 description 1
• 102000018899 Glutamate Receptors Human genes 0.000 description 1
• 108010068370 Glutens Proteins 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 108010001483 Glycogen Synthase Proteins 0.000 description 1
• 102100033851 Gonadotropin-releasing hormone receptor Human genes 0.000 description 1
• 206010018634 Gouty Arthritis Diseases 0.000 description 1
• 208000009329 Graft vs Host Disease Diseases 0.000 description 1
• 108010092372 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Proteins 0.000 description 1
• 102000016355 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Human genes 0.000 description 1
• 208000003807 Graves Disease Diseases 0.000 description 1
• 208000015023 Graves' disease Diseases 0.000 description 1
• 108010051696 Growth Hormone Proteins 0.000 description 1
• 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
• 108010010369 HIV Protease Proteins 0.000 description 1
• 101150104779 HTR2A gene Proteins 0.000 description 1
• 102100034405 Headcase protein homolog Human genes 0.000 description 1
• 108010061414 Hepatocyte Nuclear Factor 1-beta Proteins 0.000 description 1
• 102100022123 Hepatocyte nuclear factor 1-beta Human genes 0.000 description 1
• 102100024233 High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A Human genes 0.000 description 1
• 102000003834 Histamine H1 Receptors Human genes 0.000 description 1
• 108090000110 Histamine H1 Receptors Proteins 0.000 description 1
• 102000003710 Histamine H2 Receptors Human genes 0.000 description 1
• 108090000050 Histamine H2 Receptors Proteins 0.000 description 1
• 102000004187 Histamine H4 receptors Human genes 0.000 description 1
• 108090000796 Histamine H4 receptors Proteins 0.000 description 1
• 102000000543 Histamine Receptors Human genes 0.000 description 1
• 108010002059 Histamine Receptors Proteins 0.000 description 1
• 229940122236 Histamine receptor antagonist Drugs 0.000 description 1
• 108010014095 Histidine decarboxylase Proteins 0.000 description 1
• 102100037095 Histidine decarboxylase Human genes 0.000 description 1
• 102000003964 Histone deacetylase Human genes 0.000 description 1
• 108090000353 Histone deacetylase Proteins 0.000 description 1
• 102100021453 Histone deacetylase 5 Human genes 0.000 description 1
• 108050004676 Histone deacetylase 5 Proteins 0.000 description 1
• 102100022103 Histone-lysine N-methyltransferase 2A Human genes 0.000 description 1
• 101000897477 Homo sapiens C-C motif chemokine 28 Proteins 0.000 description 1
• 101000838967 Homo sapiens E3 ubiquitin-protein ligase synoviolin Proteins 0.000 description 1
• 101000893710 Homo sapiens Galactoside alpha-(1,2)-fucosyltransferase 2 Proteins 0.000 description 1
• 101001066896 Homo sapiens Headcase protein homolog Proteins 0.000 description 1
• 101001117267 Homo sapiens High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A Proteins 0.000 description 1
• 101001045846 Homo sapiens Histone-lysine N-methyltransferase 2A Proteins 0.000 description 1
• 101000606465 Homo sapiens Inactive tyrosine-protein kinase 7 Proteins 0.000 description 1
• 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
• 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 1
• 101000677891 Homo sapiens Iron-sulfur clusters transporter ABCB7, mitochondrial Proteins 0.000 description 1
• 101000916628 Homo sapiens Macrophage colony-stimulating factor 1 Proteins 0.000 description 1
• 101000979001 Homo sapiens Methionine aminopeptidase 2 Proteins 0.000 description 1
• 101000969087 Homo sapiens Microtubule-associated protein 2 Proteins 0.000 description 1
• 101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 description 1
• 101000628967 Homo sapiens Mitogen-activated protein kinase 11 Proteins 0.000 description 1
• 101000628954 Homo sapiens Mitogen-activated protein kinase 12 Proteins 0.000 description 1
• 101000628968 Homo sapiens Mitogen-activated protein kinase 13 Proteins 0.000 description 1
• 101000950695 Homo sapiens Mitogen-activated protein kinase 8 Proteins 0.000 description 1
• 101001018196 Homo sapiens Mitogen-activated protein kinase kinase kinase 5 Proteins 0.000 description 1
• 101001055091 Homo sapiens Mitogen-activated protein kinase kinase kinase 8 Proteins 0.000 description 1
• 101000735566 Homo sapiens Protein-arginine deiminase type-4 Proteins 0.000 description 1
• 101000777293 Homo sapiens Serine/threonine-protein kinase Chk1 Proteins 0.000 description 1
• 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
• 101000635804 Homo sapiens Tissue factor Proteins 0.000 description 1
• 101000713585 Homo sapiens Tubulin beta-4A chain Proteins 0.000 description 1
• 101000708573 Homo sapiens Y+L amino acid transporter 2 Proteins 0.000 description 1
• 101001117146 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Proteins 0.000 description 1
• 101000818522 Homo sapiens fMet-Leu-Phe receptor Proteins 0.000 description 1
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
• 102000002265 Human Growth Hormone Human genes 0.000 description 1
• 108010000521 Human Growth Hormone Proteins 0.000 description 1
• 239000000854 Human Growth Hormone Substances 0.000 description 1
• 108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 description 1
• 108090000144 Human Proteins Proteins 0.000 description 1
• 102000003839 Human Proteins Human genes 0.000 description 1
• 208000023105 Huntington disease Diseases 0.000 description 1
• 102000004157 Hydrolases Human genes 0.000 description 1
• 108090000604 Hydrolases Proteins 0.000 description 1
• VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
• 208000037147 Hypercalcaemia Diseases 0.000 description 1
• 206010021067 Hypopituitarism Diseases 0.000 description 1
• 206010021074 Hypoplastic anaemia Diseases 0.000 description 1
• 238000004566 IR spectroscopy Methods 0.000 description 1
• ANMATWQYLIFGOK-UHFFFAOYSA-N Iguratimod Chemical compound CS(=O)(=O)NC1=CC=2OC=C(NC=O)C(=O)C=2C=C1OC1=CC=CC=C1 ANMATWQYLIFGOK-UHFFFAOYSA-N 0.000 description 1
• 108060003951 Immunoglobulin Proteins 0.000 description 1
• 102100039813 Inactive tyrosine-protein kinase 7 Human genes 0.000 description 1
• 208000004575 Infectious Arthritis Diseases 0.000 description 1
• 108010009595 Inorganic Pyrophosphatase Proteins 0.000 description 1
• 102000009617 Inorganic Pyrophosphatase Human genes 0.000 description 1
• 102000004877 Insulin Human genes 0.000 description 1
• 108090001061 Insulin Proteins 0.000 description 1
• 108010001127 Insulin Receptor Proteins 0.000 description 1
• 102100036721 Insulin receptor Human genes 0.000 description 1
• 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
• 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
• 102100025320 Integrin alpha-11 Human genes 0.000 description 1
• 101710123196 Integrin alpha-11 Proteins 0.000 description 1
• 102100032818 Integrin alpha-4 Human genes 0.000 description 1
• 102100022337 Integrin alpha-V Human genes 0.000 description 1
• 108010041012 Integrin alpha4 Proteins 0.000 description 1
• 102000003996 Interferon-beta Human genes 0.000 description 1
• 108090000467 Interferon-beta Proteins 0.000 description 1
• 102100039064 Interleukin-3 Human genes 0.000 description 1
• 108010002386 Interleukin-3 Proteins 0.000 description 1
• 102100026019 Interleukin-6 Human genes 0.000 description 1
• 108010063738 Interleukins Proteins 0.000 description 1
• 102000015696 Interleukins Human genes 0.000 description 1
• 108010036012 Iodide peroxidase Proteins 0.000 description 1
• 102100021504 Iron-sulfur clusters transporter ABCB7, mitochondrial Human genes 0.000 description 1
• 102400000471 Isomaltase Human genes 0.000 description 1
• 206010023198 Joint ankylosis Diseases 0.000 description 1
• 206010023232 Joint swelling Diseases 0.000 description 1
• 102100031819 Kappa-type opioid receptor Human genes 0.000 description 1
• 102100035792 Kininogen-1 Human genes 0.000 description 1
• 108010077861 Kininogens Proteins 0.000 description 1
• 108010093008 Kinins Proteins 0.000 description 1
• 102000002397 Kinins Human genes 0.000 description 1
• 102000004016 L-Type Calcium Channels Human genes 0.000 description 1
• 108090000420 L-Type Calcium Channels Proteins 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
• 229930182816 L-glutamine Natural products 0.000 description 1
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
• 108010021290 LHRH Receptors Proteins 0.000 description 1
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
• NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
• 102100025357 Lipid-phosphate phosphatase Human genes 0.000 description 1
• 239000000867 Lipoxygenase Inhibitor Substances 0.000 description 1
• 102000003820 Lipoxygenases Human genes 0.000 description 1
• 108090000128 Lipoxygenases Proteins 0.000 description 1
• 206010025323 Lymphomas Diseases 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• 108020002496 Lysophospholipase Proteins 0.000 description 1
• 102000006305 Lysosphingolipid Receptors Human genes 0.000 description 1
• 108010083351 Lysosphingolipid Receptors Proteins 0.000 description 1
• 108010075645 MAP Kinase Kinase Kinase 3 Proteins 0.000 description 1
• 102100034069 MAP kinase-activated protein kinase 2 Human genes 0.000 description 1
• 102100028397 MAP kinase-activated protein kinase 3 Human genes 0.000 description 1
• 101710141393 MAP kinase-activated protein kinase 3 Proteins 0.000 description 1
• 108010041955 MAP-kinase-activated kinase 2 Proteins 0.000 description 1
• 108700012928 MAPK14 Proteins 0.000 description 1
• 229940124647 MEK inhibitor Drugs 0.000 description 1
• 108010058398 Macrophage Colony-Stimulating Factor Receptor Proteins 0.000 description 1
• 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 1
• 102100027998 Macrophage metalloelastase Human genes 0.000 description 1
• 101710187853 Macrophage metalloelastase Proteins 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
• GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• 108010076503 Matrix Metalloproteinase 13 Proteins 0.000 description 1
• 108010016165 Matrix Metalloproteinase 2 Proteins 0.000 description 1
• 108010016160 Matrix Metalloproteinase 3 Proteins 0.000 description 1
• 102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 1
• 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
• ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
• 101710113100 Membrane-bound alkaline phosphatase Proteins 0.000 description 1
• 206010027259 Meningitis tuberculous Diseases 0.000 description 1
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
• 108090000192 Methionyl aminopeptidases Proteins 0.000 description 1
• 102000016397 Methyltransferase Human genes 0.000 description 1
• 108060004795 Methyltransferase Proteins 0.000 description 1
• 102100031545 Microsomal triglyceride transfer protein large subunit Human genes 0.000 description 1
• 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
• 108090000375 Mineralocorticoid Receptors Proteins 0.000 description 1
• 102100021316 Mineralocorticoid receptor Human genes 0.000 description 1
• 108700036166 Mitogen-Activated Protein Kinase 11 Proteins 0.000 description 1
• 108700027648 Mitogen-Activated Protein Kinase 8 Proteins 0.000 description 1
• 108700027653 Mitogen-Activated Protein Kinase 9 Proteins 0.000 description 1
• 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 1
• 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 1
• 108700015929 Mitogen-activated protein kinase 12 Proteins 0.000 description 1
• 102100037809 Mitogen-activated protein kinase 9 Human genes 0.000 description 1
• 101710157666 Mitogen-activated protein kinase kinase 8 Proteins 0.000 description 1
• 101150101095 Mmp12 gene Proteins 0.000 description 1
• 102100028647 Mu-type opioid receptor Human genes 0.000 description 1
• 101710178223 Mu-type opioid receptor Proteins 0.000 description 1
• 241001529936 Murinae Species 0.000 description 1
• 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
• 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
• 102100035624 Muscarinic acetylcholine receptor M1 Human genes 0.000 description 1
• 108050007299 Muscarinic acetylcholine receptor M1 Proteins 0.000 description 1
• 102100036423 Muscarinic acetylcholine receptor M3 Human genes 0.000 description 1
• 108050008508 Muscarinic acetylcholine receptor M3 Proteins 0.000 description 1
• 208000031888 Mycoses Diseases 0.000 description 1
• WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
• HEKAIDKUDLCBRU-UHFFFAOYSA-N N-[4-[2-ethyl-4-(3-methylphenyl)-5-thiazolyl]-2-pyridinyl]benzamide Chemical compound S1C(CC)=NC(C=2C=C(C)C=CC=2)=C1C(C=1)=CC=NC=1NC(=O)C1=CC=CC=C1 HEKAIDKUDLCBRU-UHFFFAOYSA-N 0.000 description 1
• MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
• 102100023897 NADPH-cytochrome P450 reductase Human genes 0.000 description 1
• 108010057466 NF-kappa B Proteins 0.000 description 1
• 102000003945 NF-kappa B Human genes 0.000 description 1
• 108010081372 NM23 Nucleoside Diphosphate Kinases Proteins 0.000 description 1
• 229910002651 NO3 Inorganic materials 0.000 description 1
• 206010029164 Nephrotic syndrome Diseases 0.000 description 1
• 108010025020 Nerve Growth Factor Proteins 0.000 description 1
• 102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 1
• 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 1
• 206010029240 Neuritis Diseases 0.000 description 1
• 102000009493 Neurokinin receptors Human genes 0.000 description 1
• 108050000302 Neurokinin receptors Proteins 0.000 description 1
• 108010040718 Neurokinin-1 Receptors Proteins 0.000 description 1
• 108010040722 Neurokinin-2 Receptors Proteins 0.000 description 1
• PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
• NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
• 229940123134 Nitric oxide inhibitor Drugs 0.000 description 1
• 102100028646 Nociceptin receptor Human genes 0.000 description 1
• 108010015847 Non-Receptor Type 1 Protein Tyrosine Phosphatase Proteins 0.000 description 1
• 102100023252 Nucleoside diphosphate kinase A Human genes 0.000 description 1
• 101710128228 O-methyltransferase Proteins 0.000 description 1
• 208000008589 Obesity Diseases 0.000 description 1
• 239000005642 Oleic acid Substances 0.000 description 1
• ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
• 108010026867 Oligo-1,6-Glucosidase Proteins 0.000 description 1
• 102000003840 Opioid Receptors Human genes 0.000 description 1
• 108090000137 Opioid Receptors Proteins 0.000 description 1
• 208000003435 Optic Neuritis Diseases 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 102000004264 Osteopontin Human genes 0.000 description 1
• 108010081689 Osteopontin Proteins 0.000 description 1
• 208000001132 Osteoporosis Diseases 0.000 description 1
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
• 102000004316 Oxidoreductases Human genes 0.000 description 1
• 108090000854 Oxidoreductases Proteins 0.000 description 1
• BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
• UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 description 1
• 102000008212 P-Selectin Human genes 0.000 description 1
• 108010035766 P-Selectin Proteins 0.000 description 1
• 101700056750 PAK1 Proteins 0.000 description 1
• 108010070503 PAR-2 Receptor Proteins 0.000 description 1
• 108010027220 PEGylated soluble tumor necrosis factor receptor I Proteins 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 229930012538 Paclitaxel Natural products 0.000 description 1
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
• 206010033645 Pancreatitis Diseases 0.000 description 1
• 206010033647 Pancreatitis acute Diseases 0.000 description 1
• 206010033649 Pancreatitis chronic Diseases 0.000 description 1
• 108010058828 Parathyroid Hormone Receptors Proteins 0.000 description 1
• 102000006461 Parathyroid Hormone Receptors Human genes 0.000 description 1
• 101710149426 Parathyroid hormone 2 receptor Proteins 0.000 description 1
• 102100030869 Parathyroid hormone 2 receptor Human genes 0.000 description 1
• 208000018737 Parkinson disease Diseases 0.000 description 1
• 208000031481 Pathologic Constriction Diseases 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 241000721454 Pemphigus Species 0.000 description 1
• 229930182555 Penicillin Natural products 0.000 description 1
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
• 108700020474 Penicillin-Binding Proteins Proteins 0.000 description 1
• 208000008469 Peptic Ulcer Diseases 0.000 description 1
• 102100034539 Peptidyl-prolyl cis-trans isomerase A Human genes 0.000 description 1
• 206010069493 Perennial allergy Diseases 0.000 description 1
• 239000004264 Petrolatum Substances 0.000 description 1
• 102100028251 Phosphoglycerate kinase 1 Human genes 0.000 description 1
• 101710139464 Phosphoglycerate kinase 1 Proteins 0.000 description 1
• 108010064785 Phospholipases Proteins 0.000 description 1
• 102000015439 Phospholipases Human genes 0.000 description 1
• 108010058864 Phospholipases A2 Proteins 0.000 description 1
• OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
• 108010064071 Phosphorylase Kinase Proteins 0.000 description 1
• 102000014750 Phosphorylase Kinase Human genes 0.000 description 1
• 102000013566 Plasminogen Human genes 0.000 description 1
• 108010051456 Plasminogen Proteins 0.000 description 1
• 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 1
• 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 1
• 108700023400 Platelet-activating factor receptors Proteins 0.000 description 1
• 206010035664 Pneumonia Diseases 0.000 description 1
• 206010035669 Pneumonia aspiration Diseases 0.000 description 1
• 206010036030 Polyarthritis Diseases 0.000 description 1
• 239000004793 Polystyrene Substances 0.000 description 1
• 208000004880 Polyuria Diseases 0.000 description 1
• 102000004257 Potassium Channel Human genes 0.000 description 1
• 102100032709 Potassium-transporting ATPase alpha chain 2 Human genes 0.000 description 1
• 108010071690 Prealbumin Proteins 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• 101710101148 Probable 6-oxopurine nucleoside phosphorylase Proteins 0.000 description 1
• 102100025803 Progesterone receptor Human genes 0.000 description 1
• 102000056251 Prolyl Oligopeptidases Human genes 0.000 description 1
• 101710178372 Prolyl endopeptidase Proteins 0.000 description 1
• 102100023832 Prolyl endopeptidase FAP Human genes 0.000 description 1
• 102100026476 Prostacyclin receptor Human genes 0.000 description 1
• 102000008866 Prostaglandin E receptors Human genes 0.000 description 1
• 108010088540 Prostaglandin E receptors Proteins 0.000 description 1
• 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
• 108091006335 Prostaglandin I receptors Proteins 0.000 description 1
• 102000004226 Prostaglandin-E Synthases Human genes 0.000 description 1
• 108090000748 Prostaglandin-E Synthases Proteins 0.000 description 1
• 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
• 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
• 101800001753 Protease Proteins 0.000 description 1
• 239000004365 Protease Substances 0.000 description 1
• 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
• 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
• 102000001708 Protein Isoforms Human genes 0.000 description 1
• 108010029485 Protein Isoforms Proteins 0.000 description 1
• 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 1
• 102100024924 Protein kinase C alpha type Human genes 0.000 description 1
• 101710109947 Protein kinase C alpha type Proteins 0.000 description 1
• 102100021566 Protein kinase C theta type Human genes 0.000 description 1
• 101710171617 Protein kinase C theta type Proteins 0.000 description 1
• 102100021538 Protein kinase C zeta type Human genes 0.000 description 1
• 102100035731 Protein-arginine deiminase type-4 Human genes 0.000 description 1
• 102100037787 Protein-tyrosine kinase 2-beta Human genes 0.000 description 1
• 102100037132 Proteinase-activated receptor 2 Human genes 0.000 description 1
• 108010089836 Proto-Oncogene Proteins c-met Proteins 0.000 description 1
• 102000008022 Proto-Oncogene Proteins c-met Human genes 0.000 description 1
• 108010083204 Proton Pumps Proteins 0.000 description 1
• 208000020410 Psoriasis-related juvenile idiopathic arthritis Diseases 0.000 description 1
• 102000030764 Purine-nucleoside phosphorylase Human genes 0.000 description 1
• 102000002294 Purinergic P2X Receptors Human genes 0.000 description 1
• 108010000836 Purinergic P2X Receptors Proteins 0.000 description 1
• 102000000033 Purinergic Receptors Human genes 0.000 description 1
• 108010080192 Purinergic Receptors Proteins 0.000 description 1
• 102000053067 Pyruvate Dehydrogenase Acetyl-Transferring Kinase Human genes 0.000 description 1
• 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
• 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
• 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
• 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
• 208000025747 Rheumatic disease Diseases 0.000 description 1
• 240000003152 Rhus chinensis Species 0.000 description 1
• 235000014220 Rhus chinensis Nutrition 0.000 description 1
• 102000002278 Ribosomal Proteins Human genes 0.000 description 1
• 108010000605 Ribosomal Proteins Proteins 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• 102220469221 S-adenosyl-L-methionine-dependent tRNA 4-demethylwyosine synthase TYW1B_E18A_mutation Human genes 0.000 description 1
• 101150040428 SEC4 gene Proteins 0.000 description 1
• 108010017324 STAT3 Transcription Factor Proteins 0.000 description 1
• 101001117144 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) [Pyruvate dehydrogenase (acetyl-transferring)] kinase 1, mitochondrial Proteins 0.000 description 1
• 206010048908 Seasonal allergy Diseases 0.000 description 1
• 206010039792 Seborrhoea Diseases 0.000 description 1
• 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
• 206010039807 Secondary adrenocortical insufficiency Diseases 0.000 description 1
• GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
• 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
• 102100031081 Serine/threonine-protein kinase Chk1 Human genes 0.000 description 1
• 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
• 101710125350 Serine/threonine-protein kinase N1 Proteins 0.000 description 1
• 102100027910 Serine/threonine-protein kinase PAK 1 Human genes 0.000 description 1
• 101710148167 Serine/threonine-protein kinase PAK 2 Proteins 0.000 description 1
• 102100027939 Serine/threonine-protein kinase PAK 2 Human genes 0.000 description 1
• 108010012996 Serotonin Plasma Membrane Transport Proteins Proteins 0.000 description 1
• 108010089417 Sex Hormone-Binding Globulin Proteins 0.000 description 1
• 102000034755 Sex Hormone-Binding Globulin Human genes 0.000 description 1
• 101710173825 Short transient receptor potential channel 5 Proteins 0.000 description 1
• 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 1
• 206010040825 Skin depigmentation Diseases 0.000 description 1
• 108010052164 Sodium Channels Proteins 0.000 description 1
• 102000018674 Sodium Channels Human genes 0.000 description 1
• 102100033928 Sodium-dependent dopamine transporter Human genes 0.000 description 1
• 101710114615 Sodium-dependent dopamine transporter Proteins 0.000 description 1
• 101710114597 Sodium-dependent serotonin transporter Proteins 0.000 description 1
• 102000007637 Soluble Guanylyl Cyclase Human genes 0.000 description 1
• 108010007205 Soluble Guanylyl Cyclase Proteins 0.000 description 1
• 102000004584 Somatomedin Receptors Human genes 0.000 description 1
• 108010017622 Somatomedin Receptors Proteins 0.000 description 1
• 102000013275 Somatomedins Human genes 0.000 description 1
• 102100038803 Somatotropin Human genes 0.000 description 1
• 239000004147 Sorbitan trioleate Substances 0.000 description 1
• PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
• 102100027662 Sphingosine kinase 2 Human genes 0.000 description 1
• 101710156532 Sphingosine kinase 2 Proteins 0.000 description 1
• 201000002661 Spondylitis Diseases 0.000 description 1
• 102000005782 Squalene Monooxygenase Human genes 0.000 description 1
• 108020003891 Squalene monooxygenase Proteins 0.000 description 1
• 101000882403 Staphylococcus aureus Enterotoxin type C-2 Proteins 0.000 description 1
• 108010039445 Stem Cell Factor Proteins 0.000 description 1
• 108010090804 Streptavidin Proteins 0.000 description 1
• QTENRWWVYAAPBI-YZTFXSNBSA-N Streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O QTENRWWVYAAPBI-YZTFXSNBSA-N 0.000 description 1
• 101710108790 Stromelysin-1 Proteins 0.000 description 1
• 102100037342 Substance-K receptor Human genes 0.000 description 1
• 102100037346 Substance-P receptor Human genes 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
• 108010091821 Sulfonylurea Receptors Proteins 0.000 description 1
• 102000018692 Sulfonylurea Receptors Human genes 0.000 description 1
• 102000004896 Sulfotransferases Human genes 0.000 description 1
• 108090001033 Sulfotransferases Proteins 0.000 description 1
• 229940100514 Syk tyrosine kinase inhibitor Drugs 0.000 description 1
• 206010042742 Sympathetic ophthalmia Diseases 0.000 description 1
• 239000000150 Sympathomimetic Substances 0.000 description 1
• 201000010814 Synostosis Diseases 0.000 description 1
• 102000011040 TRPV Cation Channels Human genes 0.000 description 1
• 108010062740 TRPV Cation Channels Proteins 0.000 description 1
• QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
• CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
• 208000004760 Tenosynovitis Diseases 0.000 description 1
• 108010022394 Threonine synthase Proteins 0.000 description 1
• 108090000190 Thrombin Proteins 0.000 description 1
• 102000003790 Thrombin receptors Human genes 0.000 description 1
• 108090000166 Thrombin receptors Proteins 0.000 description 1
• 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
• 102100026966 Thrombomodulin Human genes 0.000 description 1
• 108010079274 Thrombomodulin Proteins 0.000 description 1
• 102000036693 Thrombopoietin Human genes 0.000 description 1
• 108010041111 Thrombopoietin Proteins 0.000 description 1
• 108010070774 Thrombopoietin Receptors Proteins 0.000 description 1
• 102100034196 Thrombopoietin receptor Human genes 0.000 description 1
• 102100027188 Thyroid peroxidase Human genes 0.000 description 1
• 102100030859 Tissue factor Human genes 0.000 description 1
• 102100030951 Tissue factor pathway inhibitor Human genes 0.000 description 1
• 102000004357 Transferases Human genes 0.000 description 1
• 108090000992 Transferases Proteins 0.000 description 1
• 102100029290 Transthyretin Human genes 0.000 description 1
• HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
• 206010044608 Trichiniasis Diseases 0.000 description 1
• DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
• 208000022971 Tuberculous meningitis Diseases 0.000 description 1
• 102100036788 Tubulin beta-4A chain Human genes 0.000 description 1
• 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 1
• 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
• 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 1
• 108010037581 Type 5 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 1
• 108010037622 Type 7 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 1
• 102000010984 Type 7 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 1
• 108010046308 Type II DNA Topoisomerases Proteins 0.000 description 1
• 102000007537 Type II DNA Topoisomerases Human genes 0.000 description 1
• 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
• 102000003425 Tyrosinase Human genes 0.000 description 1
• 108060008724 Tyrosinase Proteins 0.000 description 1
• 102100033001 Tyrosine-protein phosphatase non-receptor type 1 Human genes 0.000 description 1
• 102000044159 Ubiquitin Human genes 0.000 description 1
• 108090000848 Ubiquitin Proteins 0.000 description 1
• 208000025865 Ulcer Diseases 0.000 description 1
• 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
• 208000024780 Urticaria Diseases 0.000 description 1
• 102000009520 Vascular Endothelial Growth Factor C Human genes 0.000 description 1
• 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 description 1
• 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 1
• 101710160666 Vascular cell adhesion protein 1 Proteins 0.000 description 1
• 102000004136 Vasopressin Receptors Human genes 0.000 description 1
• 108090000643 Vasopressin Receptors Proteins 0.000 description 1
• 208000036142 Viral infection Diseases 0.000 description 1
• 206010047642 Vitiligo Diseases 0.000 description 1
• 108010048673 Vitronectin Receptors Proteins 0.000 description 1
• 208000016807 X-linked intellectual disability-macrocephaly-macroorchidism syndrome Diseases 0.000 description 1
• 102100032803 Y+L amino acid transporter 2 Human genes 0.000 description 1
• OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 description 1
• 102100024148 [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Human genes 0.000 description 1
• 101710159466 [Pyruvate dehydrogenase (acetyl-transferring)] kinase, mitochondrial Proteins 0.000 description 1
• YQRZMINCDLZPDL-UHFFFAOYSA-N [amino(phenylmethoxy)phosphanyl]oxymethylbenzene Chemical compound C=1C=CC=CC=1COP(N)OCC1=CC=CC=C1 YQRZMINCDLZPDL-UHFFFAOYSA-N 0.000 description 1
• 229960003697 abatacept Drugs 0.000 description 1
• 229960004420 aceclofenac Drugs 0.000 description 1
• WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
• 239000012346 acetyl chloride Substances 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 229960005339 acitretin Drugs 0.000 description 1
• 201000004208 acquired thrombocytopenia Diseases 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 206010069351 acute lung injury Diseases 0.000 description 1
• 201000003229 acute pancreatitis Diseases 0.000 description 1
• 201000011101 acute retrobulbar neuritis Diseases 0.000 description 1
• 229960002964 adalimumab Drugs 0.000 description 1
• 102000030621 adenylate cyclase Human genes 0.000 description 1
• 108060000200 adenylate cyclase Proteins 0.000 description 1
• 239000000853 adhesive Substances 0.000 description 1
• 230000001070 adhesive effect Effects 0.000 description 1
• 230000001800 adrenalinergic effect Effects 0.000 description 1
• 239000000464 adrenergic agent Substances 0.000 description 1
• ULCUCJFASIJEOE-NPECTJMMSA-N adrenomedullin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H]1C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)[C@@H](C)O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 ULCUCJFASIJEOE-NPECTJMMSA-N 0.000 description 1
• 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
• 125000003158 alcohol group Chemical group 0.000 description 1
• 125000000217 alkyl group Chemical group 0.000 description 1
• IHUNBGSDBOWDMA-AQFIFDHZSA-N all-trans-acitretin Chemical compound COC1=CC(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1C IHUNBGSDBOWDMA-AQFIFDHZSA-N 0.000 description 1
• 208000002205 allergic conjunctivitis Diseases 0.000 description 1
• 230000000172 allergic effect Effects 0.000 description 1
• 208000028004 allergic respiratory disease Diseases 0.000 description 1
• 230000000735 allogeneic effect Effects 0.000 description 1
• 231100000360 alopecia Toxicity 0.000 description 1
• 208000004631 alopecia areata Diseases 0.000 description 1
• FLZQKRKHLSUHOR-UHFFFAOYSA-N alosetron Chemical compound CC1=NC=N[C]1CN1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FLZQKRKHLSUHOR-UHFFFAOYSA-N 0.000 description 1
• 229960003550 alosetron Drugs 0.000 description 1
• 108090000861 alpha Adrenergic Receptors Proteins 0.000 description 1
• 102000004305 alpha Adrenergic Receptors Human genes 0.000 description 1
• HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
• 108090000183 alpha-2-Antiplasmin Proteins 0.000 description 1
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
• 229910052782 aluminium Inorganic materials 0.000 description 1
• 229950001163 amelubant Drugs 0.000 description 1
• 150000001408 amides Chemical class 0.000 description 1
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
• 239000003098 androgen Substances 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• 230000000954 anitussive effect Effects 0.000 description 1
• 210000003423 ankle Anatomy 0.000 description 1
• NUZWLKWWNNJHPT-UHFFFAOYSA-N anthralin Chemical compound C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O NUZWLKWWNNJHPT-UHFFFAOYSA-N 0.000 description 1
• 229940121363 anti-inflammatory agent Drugs 0.000 description 1
• 239000002260 anti-inflammatory agent Substances 0.000 description 1
• 230000001028 anti-proliverative effect Effects 0.000 description 1
• 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
• 229940125681 anticonvulsant agent Drugs 0.000 description 1
• 239000001961 anticonvulsive agent Substances 0.000 description 1
• 239000003793 antidiarrheal agent Substances 0.000 description 1
• 239000000739 antihistaminic agent Substances 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 235000006708 antioxidants Nutrition 0.000 description 1
• 239000000164 antipsychotic agent Substances 0.000 description 1
• 229940005529 antipsychotics Drugs 0.000 description 1
• 239000003435 antirheumatic agent Substances 0.000 description 1
• 239000003434 antitussive agent Substances 0.000 description 1
• 229940124584 antitussives Drugs 0.000 description 1
• 229950002889 apilimod Drugs 0.000 description 1
• 239000000158 apoptosis inhibitor Substances 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 210000000617 arm Anatomy 0.000 description 1
• 208000011775 arteriosclerosis disease Diseases 0.000 description 1
• 229940009098 aspartate Drugs 0.000 description 1
• 201000009408 aspiration pneumonitis Diseases 0.000 description 1
• 238000003149 assay kit Methods 0.000 description 1
• 208000024998 atopic conjunctivitis Diseases 0.000 description 1
• 201000008937 atopic dermatitis Diseases 0.000 description 1
• 238000010533 azeotropic distillation Methods 0.000 description 1
• 208000022362 bacterial infectious disease Diseases 0.000 description 1
• 229960004168 balsalazide Drugs 0.000 description 1
• IPOKCKJONYRRHP-FMQUCBEESA-N balsalazide Chemical compound C1=CC(C(=O)NCCC(=O)O)=CC=C1\N=N\C1=CC=C(O)C(C(O)=O)=C1 IPOKCKJONYRRHP-FMQUCBEESA-N 0.000 description 1
• 229940125717 barbiturate Drugs 0.000 description 1
• HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
• 229950000210 beclometasone dipropionate Drugs 0.000 description 1
• 229960003270 belimumab Drugs 0.000 description 1
• JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
• 229960005274 benzocaine Drugs 0.000 description 1
• 229940049706 benzodiazepine Drugs 0.000 description 1
• 150000001557 benzodiazepines Chemical class 0.000 description 1
• 235000010233 benzoic acid Nutrition 0.000 description 1
• 229940124748 beta 2 agonist Drugs 0.000 description 1
• 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
• 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
• 229940125388 beta agonist Drugs 0.000 description 1
• 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 description 1
• 108010014502 beta-3 Adrenergic Receptors Proteins 0.000 description 1
• 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
• 102000006635 beta-lactamase Human genes 0.000 description 1
• GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
• 239000000227 bioadhesive Substances 0.000 description 1
• 230000003851 biochemical process Effects 0.000 description 1
• 229960000074 biopharmaceutical Drugs 0.000 description 1
• 238000010241 blood sampling Methods 0.000 description 1
• 210000001185 bone marrow Anatomy 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• 208000026555 breast adenosis Diseases 0.000 description 1
• 230000007885 bronchoconstriction Effects 0.000 description 1
• 229960004436 budesonide Drugs 0.000 description 1
• 239000000872 buffer Substances 0.000 description 1
• 239000006172 buffering agent Substances 0.000 description 1
• RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
• 229960001736 buprenorphine Drugs 0.000 description 1
• 102100029168 cAMP-specific 3',5'-cyclic phosphodiesterase 4B Human genes 0.000 description 1
• 102100029175 cGMP-specific 3',5'-cyclic phosphodiesterase Human genes 0.000 description 1
• LWQQLNNNIPYSNX-UROSTWAQSA-N calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 description 1
• 229960002882 calcipotriol Drugs 0.000 description 1
• 239000001110 calcium chloride Substances 0.000 description 1
• 229910001628 calcium chloride Inorganic materials 0.000 description 1
• XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
• 159000000007 calcium salts Chemical class 0.000 description 1
• CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
• 235000013539 calcium stearate Nutrition 0.000 description 1
• 239000008116 calcium stearate Substances 0.000 description 1
• 238000004364 calculation method Methods 0.000 description 1
• 229960000846 camphor Drugs 0.000 description 1
• 229930008380 camphor Natural products 0.000 description 1
• MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
• 201000011510 cancer Diseases 0.000 description 1
• 229930003827 cannabinoid Natural products 0.000 description 1
• 239000003557 cannabinoid Substances 0.000 description 1
• 229940065144 cannabinoids Drugs 0.000 description 1
• 239000002775 capsule Substances 0.000 description 1
• 229960000623 carbamazepine Drugs 0.000 description 1
• FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
• 125000001589 carboacyl group Chemical group 0.000 description 1
• 239000001569 carbon dioxide Substances 0.000 description 1
• 229910002092 carbon dioxide Inorganic materials 0.000 description 1
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
• 229940105329 carboxymethylcellulose Drugs 0.000 description 1
• 230000000747 cardiac effect Effects 0.000 description 1
• 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
• 208000003295 carpal tunnel syndrome Diseases 0.000 description 1
• 230000003197 catalytic effect Effects 0.000 description 1
• ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
• 235000005487 catechin Nutrition 0.000 description 1
• 125000002091 cationic group Chemical group 0.000 description 1
• 239000013553 cell monolayer Substances 0.000 description 1
• 230000001413 cellular effect Effects 0.000 description 1
• 230000002490 cerebral effect Effects 0.000 description 1
• 125000003636 chemical group Chemical group 0.000 description 1
• 239000007795 chemical reaction product Substances 0.000 description 1
• 230000003399 chemotactic effect Effects 0.000 description 1
• 239000007910 chewable tablet Substances 0.000 description 1
• OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
• 229960001231 choline Drugs 0.000 description 1
• 230000001713 cholinergic effect Effects 0.000 description 1
• 229940048961 cholinesterase Drugs 0.000 description 1
• 239000000544 cholinesterase inhibitor Substances 0.000 description 1
• 201000004709 chorioretinitis Diseases 0.000 description 1
• 238000011097 chromatography purification Methods 0.000 description 1
• 229950001002 cianidanol Drugs 0.000 description 1
• AQIXAKUUQRKLND-UHFFFAOYSA-N cimetidine Chemical compound N#C/N=C(/NC)NCCSCC=1N=CNC=1C AQIXAKUUQRKLND-UHFFFAOYSA-N 0.000 description 1
• 229960003405 ciprofloxacin Drugs 0.000 description 1
• 238000003776 cleavage reaction Methods 0.000 description 1
• 229960004703 clobetasol propionate Drugs 0.000 description 1
• CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 description 1
• 229940105772 coagulation factor vii Drugs 0.000 description 1
• 229940105756 coagulation factor x Drugs 0.000 description 1
• 229960004126 codeine Drugs 0.000 description 1
• OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Natural products C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 1
• OROGSEYTTFOCAN-DNJOTXNNSA-O codeine(1+) Chemical compound C([C@H]1[C@H]([NH+](CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-O 0.000 description 1
• 229920001436 collagen Polymers 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 239000012230 colorless oil Substances 0.000 description 1
• 238000001816 cooling Methods 0.000 description 1
• 229920001577 copolymer Polymers 0.000 description 1
• 239000007799 cork Substances 0.000 description 1
• 210000004087 cornea Anatomy 0.000 description 1
• 230000003131 corticotrophic effect Effects 0.000 description 1
• 239000006059 cover glass Substances 0.000 description 1
• 229940111134 coxibs Drugs 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 229960000265 cromoglicic acid Drugs 0.000 description 1
• 229960001681 croscarmellose sodium Drugs 0.000 description 1
• 229960000913 crospovidone Drugs 0.000 description 1
• 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
• 239000003260 cyclooxygenase 1 inhibitor Substances 0.000 description 1
• 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
• 208000031513 cyst Diseases 0.000 description 1
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
• 235000018417 cysteine Nutrition 0.000 description 1
• 230000010250 cytokine signaling pathway Effects 0.000 description 1
• 238000004163 cytometry Methods 0.000 description 1
• 239000000850 decongestant Substances 0.000 description 1
• 229960001145 deflazacort Drugs 0.000 description 1
• FBHSPRKOSMHSIF-GRMWVWQJSA-N deflazacort Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)=N[C@@]3(C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O FBHSPRKOSMHSIF-GRMWVWQJSA-N 0.000 description 1
• 229960001251 denosumab Drugs 0.000 description 1
• 230000030609 dephosphorylation Effects 0.000 description 1
• 238000006209 dephosphorylation reaction Methods 0.000 description 1
• 238000010511 deprotection reaction Methods 0.000 description 1
• 229960003314 deracoxib Drugs 0.000 description 1
• WAZQAZKAZLXFMK-UHFFFAOYSA-N deracoxib Chemical compound C1=C(F)C(OC)=CC=C1C1=CC(C(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 WAZQAZKAZLXFMK-UHFFFAOYSA-N 0.000 description 1
• 239000007933 dermal patch Substances 0.000 description 1
• 201000001981 dermatomyositis Diseases 0.000 description 1
• 238000005828 desilylation reaction Methods 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 229960004590 diacerein Drugs 0.000 description 1
• 238000010586 diagram Methods 0.000 description 1
• 229910003460 diamond Inorganic materials 0.000 description 1
• 229960001259 diclofenac Drugs 0.000 description 1
• DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
• ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
• HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
• 230000004069 differentiation Effects 0.000 description 1
• 229960000616 diflunisal Drugs 0.000 description 1
• HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
• 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
• RBOXVHNMENFORY-DNJOTXNNSA-N dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 description 1
• 229960000920 dihydrocodeine Drugs 0.000 description 1
• 102000004419 dihydrofolate reductase Human genes 0.000 description 1
• KGGQKVJPXFSUHX-UHFFFAOYSA-N dimethyl(trifluoromethyl)silane Chemical compound C[SiH](C)C(F)(F)F KGGQKVJPXFSUHX-UHFFFAOYSA-N 0.000 description 1
• 229950010286 diolamine Drugs 0.000 description 1
• 206010013023 diphtheria Diseases 0.000 description 1
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
• 239000002988 disease modifying antirheumatic drug Substances 0.000 description 1
• 208000037765 diseases and disorders Diseases 0.000 description 1
• VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
• 239000006185 dispersion Substances 0.000 description 1
• 229960002311 dithranol Drugs 0.000 description 1
• 230000035619 diuresis Effects 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• 239000003937 drug carrier Substances 0.000 description 1
• 239000013583 drug formulation Substances 0.000 description 1
• 229940112141 dry powder inhaler Drugs 0.000 description 1
• 230000009977 dual effect Effects 0.000 description 1
• 229960002866 duloxetine Drugs 0.000 description 1
• 208000001321 ectrodactyly, ectodermal dysplasia, and cleft lip-palate syndrome 1 Diseases 0.000 description 1
• 229960002224 eculizumab Drugs 0.000 description 1
• 230000002497 edematous effect Effects 0.000 description 1
• 229950008913 edisilate Drugs 0.000 description 1
• 239000003602 elastase inhibitor Substances 0.000 description 1
• 210000001513 elbow Anatomy 0.000 description 1
• 238000004520 electroporation Methods 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 230000009762 endothelial cell differentiation Effects 0.000 description 1
• 239000002158 endotoxin Substances 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 210000001842 enterocyte Anatomy 0.000 description 1
• 208000037902 enteropathy Diseases 0.000 description 1
• 210000003979 eosinophil Anatomy 0.000 description 1
• 210000000981 epithelium Anatomy 0.000 description 1
• 230000000925 erythroid effect Effects 0.000 description 1
• 239000000262 estrogen Substances 0.000 description 1
• CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
• MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
• SBVYURPQULDJTI-UHFFFAOYSA-N ethyl n-[amino-[4-[[3-[[4-[2-(4-hydroxyphenyl)propan-2-yl]phenoxy]methyl]phenyl]methoxy]phenyl]methylidene]carbamate Chemical compound C1=CC(C(=N)NC(=O)OCC)=CC=C1OCC1=CC=CC(COC=2C=CC(=CC=2)C(C)(C)C=2C=CC(O)=CC=2)=C1 SBVYURPQULDJTI-UHFFFAOYSA-N 0.000 description 1
• 229960005293 etodolac Drugs 0.000 description 1
• XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 238000001704 evaporation Methods 0.000 description 1
• 230000008020 evaporation Effects 0.000 description 1
• 208000004526 exfoliative dermatitis Diseases 0.000 description 1
• 239000003172 expectorant agent Substances 0.000 description 1
• 238000013401 experimental design Methods 0.000 description 1
• 239000000284 extract Substances 0.000 description 1
• 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
• 208000030533 eye disease Diseases 0.000 description 1
• 102100021145 fMet-Leu-Phe receptor Human genes 0.000 description 1
• 229950008696 farnesil Drugs 0.000 description 1
• 108091022862 fatty acid binding Proteins 0.000 description 1
• PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
• 229960002428 fentanyl Drugs 0.000 description 1
• 239000012091 fetal bovine serum Substances 0.000 description 1
• 239000000835 fiber Substances 0.000 description 1
• 210000002950 fibroblast Anatomy 0.000 description 1
• 108010072257 fibroblast activation protein alpha Proteins 0.000 description 1
• 229940126864 fibroblast growth factor Drugs 0.000 description 1
• 235000019634 flavors Nutrition 0.000 description 1
• 229960000676 flunisolide Drugs 0.000 description 1
• 238000002875 fluorescence polarization Methods 0.000 description 1
• 239000006260 foam Substances 0.000 description 1
• 230000003325 follicular Effects 0.000 description 1
• 229950004923 fontolizumab Drugs 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 229940044170 formate Drugs 0.000 description 1
• 229960002848 formoterol Drugs 0.000 description 1
• BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 1
• 238000004108 freeze drying Methods 0.000 description 1
• 238000007710 freezing Methods 0.000 description 1
• 230000008014 freezing Effects 0.000 description 1
• 229940050411 fumarate Drugs 0.000 description 1
• 125000000524 functional group Chemical group 0.000 description 1
• 208000024386 fungal infectious disease Diseases 0.000 description 1
• 229960002870 gabapentin Drugs 0.000 description 1
• 108010062699 gamma-Glutamyl Hydrolase Proteins 0.000 description 1
• BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 description 1
• ZTQSADJAYQOCDD-UHFFFAOYSA-N ginsenoside-Rd2 Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OCC(O)C(O)C1O ZTQSADJAYQOCDD-UHFFFAOYSA-N 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 229960001731 gluceptate Drugs 0.000 description 1
• 239000003862 glucocorticoid Substances 0.000 description 1
• KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
• 229940050410 gluconate Drugs 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 229940097042 glucuronate Drugs 0.000 description 1
• 235000021312 gluten Nutrition 0.000 description 1
• 229960002449 glycine Drugs 0.000 description 1
• 230000013595 glycosylation Effects 0.000 description 1
• 238000006206 glycosylation reaction Methods 0.000 description 1
• 229960001743 golimumab Drugs 0.000 description 1
• 208000024908 graft versus host disease Diseases 0.000 description 1
• 238000000227 grinding Methods 0.000 description 1
• 244000144993 groups of animals Species 0.000 description 1
• 239000000122 growth hormone Substances 0.000 description 1
• 239000003966 growth inhibitor Substances 0.000 description 1
• 239000001963 growth medium Substances 0.000 description 1
• 210000002216 heart Anatomy 0.000 description 1
• 210000003709 heart valve Anatomy 0.000 description 1
• 208000014951 hematologic disease Diseases 0.000 description 1
• 208000007475 hemolytic anemia Diseases 0.000 description 1
• 229920000669 heparin Polymers 0.000 description 1
• ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
• 208000006454 hepatitis Diseases 0.000 description 1
• 231100000283 hepatitis Toxicity 0.000 description 1
• 239000000833 heterodimer Substances 0.000 description 1
• IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
• 210000003630 histaminocyte Anatomy 0.000 description 1
• 238000000265 homogenisation Methods 0.000 description 1
• 210000005260 human cell Anatomy 0.000 description 1
• 229920002674 hyaluronan Polymers 0.000 description 1
• 229960003160 hyaluronic acid Drugs 0.000 description 1
• BICAGYDGRXJYGD-UHFFFAOYSA-N hydrobromide;hydrochloride Chemical compound Cl.Br BICAGYDGRXJYGD-UHFFFAOYSA-N 0.000 description 1
• 229930195733 hydrocarbon Natural products 0.000 description 1
• 150000002430 hydrocarbons Chemical class 0.000 description 1
• LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 1
• 229960000240 hydrocodone Drugs 0.000 description 1
• 239000000017 hydrogel Substances 0.000 description 1
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
• 238000005984 hydrogenation reaction Methods 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
• 230000007062 hydrolysis Effects 0.000 description 1
• 238000006460 hydrolysis reaction Methods 0.000 description 1
• 230000003301 hydrolyzing effect Effects 0.000 description 1
• 229960001330 hydroxycarbamide Drugs 0.000 description 1
• 230000000148 hypercalcaemia Effects 0.000 description 1
• 208000030915 hypercalcemia disease Diseases 0.000 description 1
• 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
• 229950003909 iguratimod Drugs 0.000 description 1
• 229960004769 imidazole salicylate Drugs 0.000 description 1
• 230000002519 immonomodulatory effect Effects 0.000 description 1
• 229940124622 immune-modulator drug Drugs 0.000 description 1
• 230000003053 immunization Effects 0.000 description 1
• 238000002649 immunization Methods 0.000 description 1
• 102000018358 immunoglobulin Human genes 0.000 description 1
• 229960003444 immunosuppressant agent Drugs 0.000 description 1
• 229940125721 immunosuppressive agent Drugs 0.000 description 1
• 239000007943 implant Substances 0.000 description 1
• 230000001976 improved effect Effects 0.000 description 1
• 239000012535 impurity Substances 0.000 description 1
• 230000001939 inductive effect Effects 0.000 description 1
• 230000004968 inflammatory condition Effects 0.000 description 1
• 206010022000 influenza Diseases 0.000 description 1
• 229910052500 inorganic mineral Inorganic materials 0.000 description 1
• 229940125396 insulin Drugs 0.000 description 1
• 230000003993 interaction Effects 0.000 description 1
• 230000031891 intestinal absorption Effects 0.000 description 1
• 208000028774 intestinal disease Diseases 0.000 description 1
• 210000000936 intestine Anatomy 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 238000007917 intracranial administration Methods 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 238000007915 intraurethral administration Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 238000007914 intraventricular administration Methods 0.000 description 1
• 239000001573 invertase Substances 0.000 description 1
• 235000011073 invertase Nutrition 0.000 description 1
• INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
• OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical class O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 description 1
• 229960001361 ipratropium bromide Drugs 0.000 description 1
• KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 description 1
• SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
• FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
• QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
• 206010023332 keratitis Diseases 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 239000008141 laxative Substances 0.000 description 1
• 229940125722 laxative agent Drugs 0.000 description 1
• 230000000503 lectinlike effect Effects 0.000 description 1
• 229960000681 leflunomide Drugs 0.000 description 1
• VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
• 210000002414 leg Anatomy 0.000 description 1
• VNYSSYRCGWBHLG-AMOLWHMGSA-M leukotriene B4(1-) Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC([O-])=O VNYSSYRCGWBHLG-AMOLWHMGSA-M 0.000 description 1
• 201000011486 lichen planus Diseases 0.000 description 1
• 229960004194 lidocaine Drugs 0.000 description 1
• 210000003041 ligament Anatomy 0.000 description 1
• 229920006008 lipopolysaccharide Polymers 0.000 description 1
• 108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 description 1
• 239000002502 liposome Substances 0.000 description 1
• 238000004811 liquid chromatography Methods 0.000 description 1
• 239000012669 liquid formulation Substances 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• 239000003589 local anesthetic agent Substances 0.000 description 1
• 229960005015 local anesthetics Drugs 0.000 description 1
• 230000033001 locomotion Effects 0.000 description 1
• 229960001571 loperamide Drugs 0.000 description 1
• RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 1
• OXROWJKCGCOJDO-JLHYYAGUSA-N lornoxicam Chemical compound O=C1C=2SC(Cl)=CC=2S(=O)(=O)N(C)\C1=C(\O)NC1=CC=CC=N1 OXROWJKCGCOJDO-JLHYYAGUSA-N 0.000 description 1
• 229960002202 lornoxicam Drugs 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• 210000001699 lower leg Anatomy 0.000 description 1
• 229960000994 lumiracoxib Drugs 0.000 description 1
• KHPKQFYUPIUARC-UHFFFAOYSA-N lumiracoxib Chemical compound OC(=O)CC1=CC(C)=CC=C1NC1=C(F)C=CC=C1Cl KHPKQFYUPIUARC-UHFFFAOYSA-N 0.000 description 1
• 206010025135 lupus erythematosus Diseases 0.000 description 1
• 210000004698 lymphocyte Anatomy 0.000 description 1
• 230000000527 lymphocytic effect Effects 0.000 description 1
• 229960003646 lysine Drugs 0.000 description 1
• 235000018977 lysine Nutrition 0.000 description 1
• 210000002540 macrophage Anatomy 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• 229910001629 magnesium chloride Inorganic materials 0.000 description 1
• 229940091250 magnesium supplement Drugs 0.000 description 1
• 229940049920 malate Drugs 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
• 238000004949 mass spectrometry Methods 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• 210000003593 megakaryocyte Anatomy 0.000 description 1
• 229960003194 meglumine Drugs 0.000 description 1
• 229960001929 meloxicam Drugs 0.000 description 1
• 210000004379 membrane Anatomy 0.000 description 1
• 239000012528 membrane Substances 0.000 description 1
• 208000001223 meningeal tuberculosis Diseases 0.000 description 1
• 229940041616 menthol Drugs 0.000 description 1
• GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
• 229960001428 mercaptopurine Drugs 0.000 description 1
• KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
• 229960004963 mesalazine Drugs 0.000 description 1
• 229960001047 methyl salicylate Drugs 0.000 description 1
• JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
• VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
• 229960000282 metronidazole Drugs 0.000 description 1
• 239000004530 micro-emulsion Substances 0.000 description 1
• 108010038232 microsomal triglyceride transfer protein Proteins 0.000 description 1
• 239000004005 microsphere Substances 0.000 description 1
• 235000010755 mineral Nutrition 0.000 description 1
• 239000011707 mineral Substances 0.000 description 1
• 239000002480 mineral oil Substances 0.000 description 1
• 235000010446 mineral oil Nutrition 0.000 description 1
• 230000002438 mitochondrial effect Effects 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 239000003607 modifier Substances 0.000 description 1
• QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 1
• 229960001664 mometasone Drugs 0.000 description 1
• 210000001616 monocyte Anatomy 0.000 description 1
• 229960005181 morphine Drugs 0.000 description 1
• 239000012452 mother liquor Substances 0.000 description 1
• 230000003232 mucoadhesive effect Effects 0.000 description 1
• 230000000510 mucolytic effect Effects 0.000 description 1
• 229940066491 mucolytics Drugs 0.000 description 1
• 210000004877 mucosa Anatomy 0.000 description 1
• 210000004400 mucous membrane Anatomy 0.000 description 1
• 230000036457 multidrug resistance Effects 0.000 description 1
• 239000003149 muscarinic antagonist Substances 0.000 description 1
• 206010028417 myasthenia gravis Diseases 0.000 description 1
• 230000002071 myeloproliferative effect Effects 0.000 description 1
• 210000004165 myocardium Anatomy 0.000 description 1
• YKYONYBAUNKHLG-UHFFFAOYSA-N n-Propyl acetate Natural products CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 description 1
• YEQJVHQCUDMXFG-FHZYATBESA-N n-[(2s,3s,5r)-5-carbamoyl-1-(3-fluorophenyl)-3,8-dihydroxy-8-methylnonan-2-yl]quinoxaline-2-carboxamide Chemical compound C([C@@H]([C@@H](O)C[C@@H](CCC(C)(O)C)C(N)=O)NC(=O)C=1N=C2C=CC=CC2=NC=1)C1=CC=CC(F)=C1 YEQJVHQCUDMXFG-FHZYATBESA-N 0.000 description 1
• HSKAZIJJKRAJAV-KOEQRZSOSA-N n-[(e)-(3-methylphenyl)methylideneamino]-6-morpholin-4-yl-2-(2-pyridin-2-ylethoxy)pyrimidin-4-amine Chemical compound CC1=CC=CC(\C=N\NC=2N=C(OCCC=3N=CC=CC=3)N=C(C=2)N2CCOCC2)=C1 HSKAZIJJKRAJAV-KOEQRZSOSA-N 0.000 description 1
• 229960000805 nalbuphine Drugs 0.000 description 1
• NETZHAKZCGBWSS-CEDHKZHLSA-N nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 description 1
• 125000005487 naphthalate group Chemical group 0.000 description 1
• 229950006327 napsilate Drugs 0.000 description 1
• 239000007923 nasal drop Substances 0.000 description 1
• 229940100662 nasal drops Drugs 0.000 description 1
• 239000000025 natural resin Substances 0.000 description 1
• 239000006199 nebulizer Substances 0.000 description 1
• 230000001613 neoplastic effect Effects 0.000 description 1
• 229960001002 nepafenac Drugs 0.000 description 1
• QEFAQIPZVLVERP-UHFFFAOYSA-N nepafenac Chemical compound NC(=O)CC1=CC=CC(C(=O)C=2C=CC=CC=2)=C1N QEFAQIPZVLVERP-UHFFFAOYSA-N 0.000 description 1
• 210000005036 nerve Anatomy 0.000 description 1
• 229940053128 nerve growth factor Drugs 0.000 description 1
• 230000001537 neural effect Effects 0.000 description 1
• 230000000926 neurological effect Effects 0.000 description 1
• 210000000440 neutrophil Anatomy 0.000 description 1
• 235000001968 nicotinic acid Nutrition 0.000 description 1
• 239000011664 nicotinic acid Substances 0.000 description 1
• 229910052757 nitrogen Inorganic materials 0.000 description 1
• 108010020615 nociceptin receptor Proteins 0.000 description 1
• 230000003040 nociceptive effect Effects 0.000 description 1
• 238000010606 normalization Methods 0.000 description 1
• 231100000862 numbness Toxicity 0.000 description 1
• 235000020824 obesity Nutrition 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• 229960002450 ofatumumab Drugs 0.000 description 1
• 239000003921 oil Substances 0.000 description 1
• 239000002674 ointment Substances 0.000 description 1
• 229950004864 olamine Drugs 0.000 description 1
• ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
• 229960004110 olsalazine Drugs 0.000 description 1
• QQBDLJCYGRGAKP-FOCLMDBBSA-N olsalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=C(C(O)=CC=2)C(O)=O)=C1 QQBDLJCYGRGAKP-FOCLMDBBSA-N 0.000 description 1
• 231100000590 oncogenic Toxicity 0.000 description 1
• 230000002246 oncogenic effect Effects 0.000 description 1
• 239000000014 opioid analgesic Substances 0.000 description 1
• 229940005483 opioid analgesics Drugs 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 229960003104 ornithine Drugs 0.000 description 1
• PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 1
• 230000003204 osmotic effect Effects 0.000 description 1
• 230000003349 osteoarthritic effect Effects 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• NVOYVOBDTVTBDX-PMEUIYRNSA-N oxitropium Chemical compound CC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1 NVOYVOBDTVTBDX-PMEUIYRNSA-N 0.000 description 1
• 229960000797 oxitropium Drugs 0.000 description 1
• 229960002085 oxycodone Drugs 0.000 description 1
• 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
• 229960001592 paclitaxel Drugs 0.000 description 1
• 229910052763 palladium Inorganic materials 0.000 description 1
• 210000000496 pancreas Anatomy 0.000 description 1
• 108091005474 pancreatic polypeptide receptors Proteins 0.000 description 1
• 229960004662 parecoxib Drugs 0.000 description 1
• TZRHLKRLEZJVIJ-UHFFFAOYSA-N parecoxib Chemical compound C1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C(C)ON=C1C1=CC=CC=C1 TZRHLKRLEZJVIJ-UHFFFAOYSA-N 0.000 description 1
• 239000003182 parenteral nutrition solution Substances 0.000 description 1
• 239000004031 partial agonist Substances 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 230000007119 pathological manifestation Effects 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 229950000867 pegsunercept Drugs 0.000 description 1
• 229950010552 pelubiprofen Drugs 0.000 description 1
• 239000003961 penetration enhancing agent Substances 0.000 description 1
• 229940049954 penicillin Drugs 0.000 description 1
• 235000019371 penicillin G benzathine Nutrition 0.000 description 1
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
• 102000014187 peptide receptors Human genes 0.000 description 1
• 108010011903 peptide receptors Proteins 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 229940066842 petrolatum Drugs 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• XLCISDOVNFLSGO-VONOSFMSSA-N phorbol-12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(O)C1(C)C XLCISDOVNFLSGO-VONOSFMSSA-N 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 239000002953 phosphate buffered saline Substances 0.000 description 1
• WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
• 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
• 150000003906 phosphoinositides Chemical class 0.000 description 1
• 150000003904 phospholipids Chemical class 0.000 description 1
• 239000011574 phosphorus Substances 0.000 description 1
• 239000000049 pigment Substances 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 229960002702 piroxicam Drugs 0.000 description 1
• QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
• 230000001817 pituitary effect Effects 0.000 description 1
• 239000002797 plasminogen activator inhibitor Substances 0.000 description 1
• 208000018916 plastic bronchitis Diseases 0.000 description 1
• 102000030769 platelet activating factor receptor Human genes 0.000 description 1
• 208000030428 polyarticular arthritis Diseases 0.000 description 1
• 229920000642 polymer Polymers 0.000 description 1
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
• 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
• 229940068968 polysorbate 80 Drugs 0.000 description 1
• 229920000053 polysorbate 80 Polymers 0.000 description 1
• 229920002223 polystyrene Polymers 0.000 description 1
• 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
• 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
• 239000013641 positive control Substances 0.000 description 1
• 108020001213 potassium channel Proteins 0.000 description 1
• 125000001897 prednisolone group Chemical group 0.000 description 1
• AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 1
• 229960001233 pregabalin Drugs 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 230000003518 presynaptic effect Effects 0.000 description 1
• 230000003449 preventive effect Effects 0.000 description 1
• 230000008569 process Effects 0.000 description 1
• 108090000765 processed proteins & peptides Proteins 0.000 description 1
• 102000004196 processed proteins & peptides Human genes 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 108090000468 progesterone receptors Proteins 0.000 description 1
• 238000004393 prognosis Methods 0.000 description 1
• 230000001737 promoting effect Effects 0.000 description 1
• 230000000069 prophylactic effect Effects 0.000 description 1
• 235000019419 proteases Nutrition 0.000 description 1
• 108010050991 protein kinase C zeta Proteins 0.000 description 1
• 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 1
• 201000001474 proteinuria Diseases 0.000 description 1
• 208000028172 protozoa infectious disease Diseases 0.000 description 1
• 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
• MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
• ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
• 239000000376 reactant Substances 0.000 description 1
• CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 description 1
• 239000000018 receptor agonist Substances 0.000 description 1
• 229940044601 receptor agonist Drugs 0.000 description 1
• 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
• 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
• 230000009467 reduction Effects 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 201000004335 respiratory allergy Diseases 0.000 description 1
• 230000000241 respiratory effect Effects 0.000 description 1
• 208000037803 restenosis Diseases 0.000 description 1
• 208000022670 retrobulbar neuritis Diseases 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 201000007529 rheumatic myocarditis Diseases 0.000 description 1
• 229960001487 rimexolone Drugs 0.000 description 1
• QTTRZHGPGKRAFB-OOKHYKNYSA-N rimexolone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CC)(C)[C@@]1(C)C[C@@H]2O QTTRZHGPGKRAFB-OOKHYKNYSA-N 0.000 description 1
• 229960000371 rofecoxib Drugs 0.000 description 1
• RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
• 229960001549 ropivacaine Drugs 0.000 description 1
• 229960004586 rosiglitazone Drugs 0.000 description 1
• 102220082846 rs373113507 Human genes 0.000 description 1
• 229960004017 salmeterol Drugs 0.000 description 1
• 238000005070 sampling Methods 0.000 description 1
• 201000000306 sarcoidosis Diseases 0.000 description 1
• 229920006395 saturated elastomer Polymers 0.000 description 1
• 230000037390 scarring Effects 0.000 description 1
• HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
• 230000007017 scission Effects 0.000 description 1
• 239000000565 sealant Substances 0.000 description 1
• 230000001932 seasonal effect Effects 0.000 description 1
• 230000028327 secretion Effects 0.000 description 1
• 239000000932 sedative agent Substances 0.000 description 1
• 239000013049 sediment Substances 0.000 description 1
• 201000001223 septic arthritis Diseases 0.000 description 1
• 238000013207 serial dilution Methods 0.000 description 1
• 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
• 239000012679 serum free medium Substances 0.000 description 1
• 230000035939 shock Effects 0.000 description 1
• 108010085082 sigma receptors Proteins 0.000 description 1
• 230000019491 signal transduction Effects 0.000 description 1
• 229960003310 sildenafil Drugs 0.000 description 1
• 239000000377 silicon dioxide Substances 0.000 description 1
• 229960002930 sirolimus Drugs 0.000 description 1
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
• 208000017520 skin disease Diseases 0.000 description 1
• 210000000813 small intestine Anatomy 0.000 description 1
• 210000002460 smooth muscle Anatomy 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
• 239000003195 sodium channel blocking agent Substances 0.000 description 1
• 239000011780 sodium chloride Substances 0.000 description 1
• HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
• 229940001584 sodium metabisulfite Drugs 0.000 description 1
• 235000010262 sodium metabisulphite Nutrition 0.000 description 1
• 159000000000 sodium salts Chemical class 0.000 description 1
• 239000008109 sodium starch glycolate Substances 0.000 description 1
• 229940079832 sodium starch glycolate Drugs 0.000 description 1
• 229920003109 sodium starch glycolate Polymers 0.000 description 1
• 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
• 230000000392 somatic effect Effects 0.000 description 1
• 235000019337 sorbitan trioleate Nutrition 0.000 description 1
• 229960000391 sorbitan trioleate Drugs 0.000 description 1
• 229960002920 sorbitol Drugs 0.000 description 1
• 238000002798 spectrophotometry method Methods 0.000 description 1
• 238000001228 spectrum Methods 0.000 description 1
• 150000003408 sphingolipids Chemical class 0.000 description 1
• 208000020431 spinal cord injury Diseases 0.000 description 1
• 238000001694 spray drying Methods 0.000 description 1
• 238000010922 spray-dried dispersion Methods 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• 230000036262 stenosis Effects 0.000 description 1
• 208000037804 stenosis Diseases 0.000 description 1
• 239000008223 sterile water Substances 0.000 description 1
• 108010016093 sterol O-acyltransferase 1 Proteins 0.000 description 1
• 230000004936 stimulating effect Effects 0.000 description 1
• 230000035882 stress Effects 0.000 description 1
• 208000023924 subacute bursitis Diseases 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 239000000126 substance Substances 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
• 229960004793 sucrose Drugs 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 230000009747 swallowing Effects 0.000 description 1
• 229940127230 sympathomimetic drug Drugs 0.000 description 1
• 230000001360 synchronised effect Effects 0.000 description 1
• 201000004595 synovitis Diseases 0.000 description 1
• 238000010189 synthetic method Methods 0.000 description 1
• 229920003002 synthetic resin Polymers 0.000 description 1
• 239000000057 synthetic resin Substances 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 229960001967 tacrolimus Drugs 0.000 description 1
• QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
• 229960000565 tazarotene Drugs 0.000 description 1
• IKBKZGMPCYNSLU-RGVLZGJSSA-N tegaserod Chemical compound C1=C(OC)C=C2C(/C=N/NC(=N)NCCCCC)=CNC2=C1 IKBKZGMPCYNSLU-RGVLZGJSSA-N 0.000 description 1
• 229960002876 tegaserod Drugs 0.000 description 1
• 229960000235 temsirolimus Drugs 0.000 description 1
• QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 1
• LZNWYQJJBLGYLT-UHFFFAOYSA-N tenoxicam Chemical compound OC=1C=2SC=CC=2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 LZNWYQJJBLGYLT-UHFFFAOYSA-N 0.000 description 1
• 229960002871 tenoxicam Drugs 0.000 description 1
• 229960000278 theophylline Drugs 0.000 description 1
• 238000004809 thin layer chromatography Methods 0.000 description 1
• 230000009974 thixotropic effect Effects 0.000 description 1
• 229960004072 thrombin Drugs 0.000 description 1
• 206010043554 thrombocytopenia Diseases 0.000 description 1
• 125000002480 thymidyl group Chemical group 0.000 description 1
• 102000004217 thyroid hormone receptors Human genes 0.000 description 1
• 108090000721 thyroid hormone receptors Proteins 0.000 description 1
• 210000001578 tight junction Anatomy 0.000 description 1
• LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical class O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 description 1
• 229960000257 tiotropium bromide Drugs 0.000 description 1
• 229960003989 tocilizumab Drugs 0.000 description 1
• 210000003371 toe Anatomy 0.000 description 1
• 239000012049 topical pharmaceutical composition Substances 0.000 description 1
• 238000012549 training Methods 0.000 description 1
• LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 1
• 238000013518 transcription Methods 0.000 description 1
• 230000035897 transcription Effects 0.000 description 1
• 230000001052 transient effect Effects 0.000 description 1
• 230000007704 transition Effects 0.000 description 1
• 102000027257 transmembrane receptors Human genes 0.000 description 1
• 108091008578 transmembrane receptors Proteins 0.000 description 1
• PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 1
• 229960003991 trazodone Drugs 0.000 description 1
• 229960002117 triamcinolone acetonide Drugs 0.000 description 1
• YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
• 208000003982 trichinellosis Diseases 0.000 description 1
• 201000007588 trichinosis Diseases 0.000 description 1
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
• 229960000281 trometamol Drugs 0.000 description 1
• 201000008827 tuberculosis Diseases 0.000 description 1
• 210000004881 tumor cell Anatomy 0.000 description 1
• 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
• 108010034105 type I collagen receptor Proteins 0.000 description 1
• 230000005951 type IV hypersensitivity Effects 0.000 description 1
• 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
• 108010002164 tyrosine receptor Proteins 0.000 description 1
• 231100000397 ulcer Toxicity 0.000 description 1
• 238000002604 ultrasonography Methods 0.000 description 1
• 208000009852 uremia Diseases 0.000 description 1
• 239000000105 vanilloid receptor agonist Substances 0.000 description 1
• 239000000085 vanilloid receptor antagonist Substances 0.000 description 1
• 208000019553 vascular disease Diseases 0.000 description 1
• 239000005526 vasoconstrictor agent Substances 0.000 description 1
• 210000003462 vein Anatomy 0.000 description 1
• 230000009385 viral infection Effects 0.000 description 1
• 210000001835 viscera Anatomy 0.000 description 1
• 150000002266 vitamin A derivatives Chemical class 0.000 description 1
• 239000003871 white petrolatum Substances 0.000 description 1
• 150000003751 zinc Chemical class 0.000 description 1
• XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
• 229960004276 zoledronic acid Drugs 0.000 description 1
• XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 1
• ZAFYATHCZYHLPB-UHFFFAOYSA-N zolpidem Chemical compound N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 ZAFYATHCZYHLPB-UHFFFAOYSA-N 0.000 description 1
• 229960001475 zolpidem Drugs 0.000 description 1
• 108020001588 κ-opioid receptors Proteins 0.000 description 1